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Abstract
Visceral leishmaniasis is a devastating neglected parasitic disease caused by
infection with Leishmania donovani. It life cycle has two stages with promastigote (insect
stage) and amastigote (animal stage) morphologies. Miltefosine is currently the only
commercially available oral drug available to treat leishmaniasis and recent evidence
suggests clinical resistance has emerged. Due to the importance of this drug and the
scarcity of new drugs in the pipeline, work has been done on understanding the
mechanism(s) of miltefosine, yet the mechanism of action for resistance is still not
known.
In previous studies investigators generated miltefosine resistance on the insect
vector stage (promastigotes), yet there is an important gap in understanding miltefosine
resistance in the human infectious stage (amastigotes) of the disease. Before we could
accomplish this goal a L. donovani cell line was converted into a stable, continuously
cultured axenic amastigote cell line and characterized by disease burden generated in
vitro and in vivo.
The axenic line of L. donovani (MHOM/SD/75/1246/130) retains characteristics
of amastigotes infecting macrophages and proliferated better than metacyclic
promastigotes in macrophages in vitro and hamsters. The axenic amastigote line was used
to induce miltefosine resistance by using discontinuous stepwise increasing drug
pressure. Stable high-grade resistance was established (62-fold) and characterized in vitro
and in vivo. Lastly, the fitness of miltefosine resistant versus susceptible parasite was
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established for the first time. This work adds the first efforts characterizing and
understanding the complex problem of miltefosine resistance in amastigotes.
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Chapter One:
Introduction
Leishmania: Background
Leishmania is an obligate intracellular protozoan parasite with a divalent life
cycle. It has a flagellated promastigote stage, which is found in the sand-fly vector, and
an amastigote stage with a truncated flagellum found in animals. This devastating
parasite belongs to the Leishmania genus (Domain Eukaryota, Phylum Euglenozoa, Class
Kinetoplastida, Order Trypanosomatida). A family of leishmania parasites causes the
disease leishmaniasis; 30 different species have been identified that cause various clinical
symptoms in humans (Neuber, 2008). The parasite has caused disease in people of many
cultures in the world which has resulted in a multitude of names for the disease including:
Aleppo boil, Valley sickness, Andean sickness, Leprosy of the mountains, White
Leprosy, Dum dum fever, Kala-azar (black fever), Grayish, Assam fever, and Jericho
buttons (James, Berger, & Elston, 2011).
The leishmania parasite has infected human and animals for at least 4000 years as
evident by positive amplification of leishmania kinetoplast DNA in Egyptian and Nubian
mummies (Zink, Spigelman, Schraut, Greenbalt, Nerlich, & Donoghue, 2006). However,
William Boog Leishman did not discover the cause of leishmaniasis until 1903, while
examining oval bodies (amastigotes) found in the spleen of a British soldier who died
from Dum Dum fever in India (Leishman, 1903). Charles Donovan independently found
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oval bodies (amastigotes) in patients who died from leishmaniasis (Ross, 1903). Because
of this, Ronald Ross suggested that this newly discovered organism be named after these
two men, which is now known as Leishmania donovani (Ross 1903).
Since this discovery, over one hundred years of research has been devoted to
studying leishmania in terms of epidemiology, host-parasite interaction, and drug and
vaccine discovery. Despite a century of work, progress has been slow because it is a
neglected tropical disease and a particularly complex organism. Christophers (1904) was
the first to describe in detail the pathology of L. donovani, finding that the parasites
proliferate in macrophages and aggregate in the liver, spleen, and bone marrow.
The first step to studying this parasite in the lab was learning how to culture
leishmania. Rogers was the first to grow leishmania in 1904, but the cultures could only
survive for 2 weeks (Rogers 1904). In 1909 Ch. Nicolle used Novy-McNeal medium that
was used to grow leishmania for a couple of weeks and modified it into, Nicolle-NovyMcNeal (NNN) medium which consists of bacto beef, neopeptone, bacto agar, and rabbit
blood to subculture leishmania indefinitely.
From in vitro cultures, Meleney (1925) infected hamsters and studied the
progression of the disease. Many species are capable of being infected with leishmania,
but the hamster became an important model organism for studying L. donovani (Croft,
Seifert, & Yardley, 2006). This is because they have a similar physiological response to
humans in regards the progression of disease (Croft et al., 2006; Melby, Chandrasekar,
Zhao, & Coe, 2001). A method to accurately quantify parasite burden in the tissues of
these hamsters was developed by Stauber in 1958. Stauber (1958) took impression
smears of infected organs and determined Leishman Donovan Units (LDU), which is
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calculated as organ mass (g) multiplied by the number of amastigotes per one thousand
macrophage nuclei. The development of the LDU method established a standard method
to evaluate drugs effectiveness in vivo that is still in use today.
Good in vitro models needed to be developed for primary screening of
compounds before committing to the much slower in vivo models to expedite drug
discovery. Ninety-Six well plates with serial diluted drugs and uniform numbers of
parasites can be used to determine IC50 values of drugs. Promastigotes have been used
extensively, but often the data does not correlate well with in vivo data (Gupta & Nishi,
2011). Pan developed an axenic amastigote line of L. Mexicana in 1984. Axenic
amastigote cell lines can be used to rapidly test drugs in high throughput screens that
generates data that is more relevant for drug discovery than promastigotes. A direct
counting method can also be used with infected macrophages which is the most clinically
relevant, yet most labor intensive in vitro model available (Chang, 1980). With the advent
of transfection technology it is now possible to transfect leishmania with reporter genes.
Leishmania was transfected with firefly luciferase reporter gene to easily and rapidly
quantify leishmania in macrophage and animal models in 2000 (Roy, Dumas, Sereno,
Wu, Singh, Tremblay, Ouellette, Oliver, & Papadopoulou, 2000). With the development
of these tools, the process of drug discovery and comparative infectivity and drug
susceptibility between drug resistant parasites and their sensitive parents is more
manageable and rapid.
Leishmania Life Cycle
The L. donovani life cycle is pictured in figure 1.1 (Centers for Disease Control
and Prevention [CDC], 2009). The life cycle of all leishmania species is a divalent life
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cycle with promastigotes (insect stage) and amastigotes (animal stage). The promastigote
stage can be further divided into procyclics and metacyclics. The ability of the sand-fly’s
promastigotes to undergo a sexual stage was discovered in 2009 (Akopyants, Kimblin,
Secundino, Patrick, Peters, Lawyer, Dobson, Beverley, & Sacks, 2009). Before this
recent discovery it was believed that promastigotes have always undergone asexual
division, as amastigotes are believe to do now. Leishmania posses one nucleus (N),
kinetoplast (K), and flagellum (F), each organelle duplicate during the promastigotes
replication, which leads to the following morphologies 1K1N1F, 1K1N2F, 1K2N2F, and
2K2N2F, that can be observed in culture and in the sand-fly host (Wheeler, Gluenz, &
Gull, 2011). These dividing promastigotes can be lumped together as procyclics that
grow in a log phase in both the sand-fly and in culture (Sacks & Perkins, 1984) The
promastigotes become stationary non-dividing cells at the end of the log phase called
metacyclics and this is the stage at which promastigotes are infectious (Sacks & Perkins,
1984).
Sand-fly (Definitive Host). Leishmania is transmitted to animals and humans by a sandfly vector. There are approximately 600 sand-fly species, but only 10% of them can act as
vectors of leishmaniasis (Sharma & Singh, 2008). The two main genera are Phlebotomus
(old world) and Lutzomia (new world) (Sharma & Singh, 2008). The main vectors for L.
donovani are Phlebotomus argentipes, Phlebotomus orientalis, and Phlebotomus martini
(Sharma & Singh, 2008). The female sand-flies require blood meals to obtain protein for
their egg broods and typically will travel several hundred meters from their habitat at
night and dusk to feed (Sharma & Singh, 2008). The leishmania parasite can be
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transmitted to a number of animals, including dogs, lizards, cattle, and humans (Sharma
& Singh, 2008).
Clinical Manifestation and Diagnosis in Humans (Intermediate Host). Leishmaniasis
is a polymorphic disease that manifests itself in three main forms; cutaneous,
mucocutaneous, and visceral. Different leishmania species cause different forms, but the
disease can manifest in atypical ways depending on the physiology of the person infected.
L. donovani is able to cause visceral disease because it can express heat shock proteins to
survive in the liver, spleen, and bone marrow, such as the A2 heat shock gene that is a
non-expressing pseudo gene in L. major which causes cutaneous leishmania (McCall &
Matlashewski, 2010). Without treatment, L. donovani causes nearly 100% mortality after
two years, making it the most lethal form (Chappuis, Sundar, Hailu, Ghalib, Rijal,
Peeling, Alvar, Boelaert, 2007). The mucocutaneous manifestation is associated by
viruses infecting leishmania such as the LRV1 virus (Ives, Ronet, Prevel, Ruzzante,
Fuertes-Marraco, Schutz, Zangger, Ravez-Breton, Lye, Hickerson, Beverly, Acha-Orbea,
Launois, Fasel, & Masina, 2011). Cutaneous leishmaniasis can manifest as disseminated
cutaneous leishmaniasis, which produces diffuse, non-ulcerated nodular lesions all over
the body. These lesions fail to heal spontaneously, relapse after treatment and can cause
death (Banuls, Bastien, Pomares, Arevalo, Fisa, & Hide, 2011). Post Kala-azar dermal
leishmaniasis (PKDL) manifests in L. donovani patients 1-2 years after apparently
successful treatment (Banuls, Bastien, Pomares, Arevalo, Fisa, & Hide, 2011). Post Kalaazar dermal leishmaniasis presents as hypo pigmented macules, papules, or nodules on
the face and represents 5-10 % of cases in India where most of the causes of L. donovani
occur (Banuls, Bastien, Pomares, Arevalo, Fisa, & Hide, 2011). Interestingly, some
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people who become infected become asymptomatic carriers and play an important role as
reservoirs (Banuls, Bastien, Pomares, Arevalo, Fisa, & Hide, 2011).
Global Impact of Leishmania
The leishmania parasite can be found on every continent in the world except
Antarctica. Like most neglected parasitic diseases, it is primarily a disease of poverty.
Currently, leishmaniasis is considered to be endemic in 88 countries, 72 of which are
developing countries (World Health Organization [WHO], 2012) Ninety percent of all
visceral leishmaniasis cases occur in Bangladesh, Brazil, India, Nepal and Sudan; 90% of
mucocutaneous leishmaniasis occurs in Bolivia, Brazil and Peru; 90% of cutaneous
leishmaniasis cases occur in Afghanistan, Brazil, Iran, Peru, Saudi Arabia and Syria
(WHO, 2012). Approximately two million people a year develop symptomatic cutaneous
leishmaniasis, and 10 % of those cases affecting the mucous membranes, which can be
fatal (David & Craft, 2009). There are approximately, 400,000 new cases of visceral
leishmaniasis reported each year (Alvar, Velez, Bern, Herrero, Desjeux, Cano, Jannin, &
Boer, 2012).
Kinetoplast
Leishmania is a member of the Class Kinetoplastida because of its possession of a
kinetoplast organelle, which functions as a mitochondrion. Sharing this class are the
trypanosomes, which are another group of important diseases causing parasites. It was
first shown that the kinetoplast is composed of DNA that is separate from nuclear DNA
in 1924 (Bresslau & Scremin, 1924). The kinetoplast posses two types of interlocking
rings of DNA, the minicircles and the maxicircles (Souza, Attias, & Rodrigues, 2009).
There are several thousand minicircles, which range in size from about 0.5 to 2.5 kb and
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a few dozen maxicircles, which usually vary between 20 and 40 kb (Souza, Attias, &
Rodrigues, 2009). The maxicircles have the same structure and serve the same functions
as mitochondrial DNA in higher eukaryotes, and they encode rRNAs and subunits of the
respiratory complexes. Minicircles encode guide RNAs that modify the maxicircles
transcripts by extensive uridylate insertion or deletion in a process known as RNA editing
(Souza, Attias, & Rodrigues, 2009).
Vaccines
For centuries, people in endemic countries have been infecting themselves with
leishmania lesion exudate to acquire life-long immunity to the disease (Khamesipour,
Rafati, Davoudi, Maboudi, & Modabber, 2006). The fact that an infection usually leads to
lifelong immunity gives great hope that a vaccine can be developed. There has been a lot
of work using both simple and very advanced techniques toward this goal. However, we
currently do not have an effective vaccine for humans on the market.
Some of the earliest work on leishmania vaccines was a continuation of
leishmanization, but with the use of cell culture instead of lesion exudate. However, this
practice was stopped after a few cases became chronic and did not respond to routine
treatment (Khamesipour, Rafati, Davoudi, Maboudi, & Modabber, 2006). Presently, the
only live prophylactic vaccine in use is a mixture of attenuated L. major and killed
parasite registered in Uzbekistan (Khamesipour, Rafati, Davoudi, Maboudi, & Modabber,
2006). The use of a wild type parasite as a vaccine could never be used to treat a patient
with HIV, making leishmanization too risky and impractical for most of the world.
Several live attenuated vaccines have been created in labs. These attenuated cultures
have been created by long-term culture method and have shown to be effective in mice
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models, but they have not been used in humans for fear of reversion to wild type
leishmania (Silvestre, Cordeiro-da-Silva, & Quaissi, 2008). A large area of vaccine
research involves the development of gene knockout parasites with the hope of conferring
immunity without pathogenicity. The first one created was an L. major dihydrofolate
reductase-thymidylate synthase knockout (Silvestre, Cordeiro-da-Silva, & Quaissi, 2008).
Mice treated with this vaccine had good immunity against wild type infections, but
Rhesus monkeys treated with this vaccine had no immunity (Silvestre, Cordeiro-da-Silva,
& Quaissi, 2008). L. major with the LPG2 genes knocked out showed no pathology in
BALB/c mice and showed immunity to wild type infection (Silvestre, Cordeiro-da-Silva,
& Quaissi, 2008). This vaccine may be an ideal candidate for further development, but
available literature is limited. Other knockouts include the inactivation of the biopterin
transporter in L. donovani, and CPa and CPb were knocked out in L. mexicana
(Khamesipour et al., 2006). Interestingly, a centrin gene knock-out in L. donovani has
been shown to give protection in mice and hamsters from not only L. donovani, but also
L. braziliensis (Selvapandiyan, Dey, Nylen, Duncan, Sacks, & Nakhasi, 2009).
The use of gene knockout parasites to induce protection against challenge with wild
type parasites without pathology is a very attractive prospect. However, maintaining a
knockout culture on a massive scale for vaccine distribution would require a high level of
expertise and be very difficult to maintain. A live gene knockout parasite vaccine would
have many logistical problems for distribution around the world that would need to be
addressed, if this were ever to become a viable option.
An interesting approach to live vaccine development is the use of suicidal cassettes.
In this process, genes are not knocked out, but rather inserted to induce drug sensitivity.
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An L. major strain was made double drug sensitive by inserting two genes. A modified
HSV-1 thymidine kinase gene increased sensitivity to ganciclovir (Khamesipour et al.,
2006). A Saccharomyces cerevisiae cytosine deaminase gene, added sensitivity to 5fluorocytosine (Khamesipour et al. 2006). When both of these drugs were used to treat
the parasite at the same time, the drugs worked synergistically (Khamesipour et al. 2006).
In vivo studies showed that this parasite could create a lesion in BALB/c mice and that
drugs could cure the disease in two weeks and still confer immunity to wild type after 4
months (Khamesipour et al., 2006). Two weeks is considered a very fast treatment time
for leishmaniasis. It is impressive that even a short infection time will confer immunity to
leishmania. There is no further data published on this suicide cassette but it might be a
good alternative to leishmanization. At risk populations could be infected with this
parasite and then treated quickly, hoping to reduce the chance of pathogenesis.
A safer alternative to live attenuated vaccines has been the use of killed vaccines. In
Brazil, killed L. amazonensis vaccine was dosed 3 times in a clinical trial showing some
protection. Importantly, those vaccinated required a lower dose of antimony to be cured
from natural infection (Khamesipour et al., 2006). The vaccine was registered as an
adjunct to antimony therapy in Brazil but not for prophylactic use (Khamesipour et al.,
2006). The vaccine only gave protection in 43 % of individuals (Khamesipour et al.,
2006). Currently, that vaccine with that addition of 100 µg of aluminum hydroxide is
being studied in Sudan (Khamesipour et al., 2006). The use of a conjugate vaccine with
killed leishmania is an area that should be explored further because a live leishmania
vaccine is most likely not going to be safe for use in HIV endemic areas.
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Fucose mannose ligand (FML) antigen from the parasite has been shown to induce
92-95 % protection from natural infection for up to 3.5 years in dogs (Khamesipour et al.,
2006). Developing a vaccine to be used in animals is a much easier and cost effective
process than developing one for humans. Currently, there is no effective vaccine on the
market for people and an immunocompromised population confounds that problem.
Reducing the transmission of leishmania should be a priority for public health
practitioners. Dogs are an important reservoir of the parasite in many areas of the world
and introduction of a vaccine like FML to vaccinate dogs would be of great benefit to
reduce the transmission of leishmania in those areas.
Another area of leishmania vaccine development is the use of DNA vaccines.
Currently, the genomes for L. major, L. infantum, and L. braziliensis have been
sequenced. This makes it relatively easy and inexpensive to develop vaccines. There are
several antigen candidates being considered for developing a DNA vaccine. A couple of
DNA vaccines in development were Gp63, which failed in mice, and LACK, which
conferred 60 % protection in dogs (Khamesipour et al., 2006). In order for a vaccine to be
effective for leishmania, it would probably need to target several antigens at once instead
of selecting one protein at a time. One area of research that might lead to new targets for
vaccine development is the use of proteomics and transcriptomics (Kumari, Kumar,
Samant, Singh, & Dube, 2008). It is difficult to determine what, if any, strategy will lead
to an effective and safe vaccine for humans, so it is good that several avenues are being
explored.
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Drugs and Resistance
Since a viable vaccine against leishmania beyond leishmanization is not yet
available, drug therapy is the treatment of choice, especially for visceral leishmaniasis.
Drug development for the leishmania parasite is difficult because it is a eukaryote and
survives at a low pH inside of a macrophage vacuole. A successful drug needs to activate
macrophages to kill the parasite or travel through several membranes and pH changes to
reach the parasite. Because of these limitations, few drugs are available on the market and
all have severe toxicity profiles (table 1.1). There are several drugs in clinical trials and in
earlier and others in the early stages of development, but currently the main drugs on the
market for leishmaniasis are sodium sitbogluconate, meglumine antimoniate,
amphotericin B, pentamidine, paramoycin, and miltefosine.
Antimonials. Sodium stibogluconate (Pentostam) and meglumine antimoniate
(Glucantime) are members of the antimonial class of drugs. The drugs have been the first
line of treatment for over 60 years. These pentavalent antimonials are prodrugs that get
reduced to trivalent antimonials by macrophages or amastigotes (Croft, Sundar, &
Fairlamb, 2006). The mechanism of action is a targeted effect on glutathione and
trypanothione metabolism (Croft et al., 2006). The mechanism of resistance has been
associated with inactivation of aquaglycoporins mediated uptake of trivalent antimonials
(Croft et al., 2006). There are many other proposed mechanisms of resistance, but they
have not been studied extensively in clinical isolates. However, the widespread nature of
resistance to antimonals in India, especially Bihar has led to the development and
deployment of other drugs.
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Amphotericin B. Amphotericin B is a polyene antibiotic that targets ergosterol in favor
of sterol, which is prevalent in leishmania (Croft et al., 2006). Amphotericin B resistance
was thought to be unlikely by some, but it has recently emerged in the field (Purkait,
Kumar, Nandi, Sardar, Das, Kumar, Pandey, Ravidas, Kumar, De, Singh, & Das, 2002).
It has been found that amphotericin B resistant clinical isolates have increased membrane
fluidity, decreased potassium resulting in higher membrane depolarization, and increased
expression in SCMT B and MDR1 genes (Purkait et al., 2002). Interestingly, the
amphotericin B resistant parasites’ major sterol was cholesa-5, 7, 24-trien-3β-ol, instead
of ergosterol, which effectively eliminates Amphotericin B’s target (Purkait et al., 2002).
Pentamidine. Pentamidine has been primarily used as a second line drug for the past 40
years. Its proposed mechanism of action is inhibition of polyamine biosynthesis, DNA
minor groove binding, and effects on mitochondrial inter membrane potential (Croft et
al., 2006). In pentamidine resistant lines, the drug is found in the cytosol and not
accumulated in the mitochondrion, as found in sensitive parasites (Basselin, Denise,
Coombs, & Barrett, 2002). The two main mechanisms of pentamidine resistance is
expression of ABC transporters to efflux the drug and mutations in the PRP1 gene
(Coelho, Gentil, Silveria, & Cortrim, 2008).
Paraomoycin. Paraomoycin is an aminoglycoside-aminocyclitol antibiotic (Croft et al.,
2006). Resistant lines of leishmania were found to have up regulation of ribosomal
proteins and increased levels of glycolytic enzymes and stress proteins (Chawla,
Jhingram, Panigrahi, Stuart, & Madhubala, 2011). Also, the resistant strain had up
regulation in proteins involved in intracellular survival and vesicular trafficking (Chawla
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et al., 2011). This drug has not yet become resistant in the field, so studies on clinical
isolates are not yet possible.
Azoles. The azoles, which include the anitleishmanial drugs, ketoconazole, and
itraconazole inhibit C14 α-demethylase, which is part of ergosterol biosynthesis (Croft et
al., 2006). The literature on azole resistance in leishmania is minimal. What we do know
is that a resistant phenotype can be generated when the cosItz region is overexpressed
(Camizotti, Yamashiro-Kanashiro, & Cotrim, 2009). However, future work will probably
show other drug resistance mechanism involving the ergosterol biosynthetic pathway.
Miltefosine. Miltefosine is the first and only oral drug on the market for leishmania,
which was originally a rejected cancer drug. Miltefosine is an alkyl-lysophospholipid and
its mechanism of action on leishmania is poorly understood. It is believed that miltefosine
induces apoptosis and inhibition of phosphatidyl choline (Arthur & Bittman, 1998).
Despite a clear understanding of its mechanism of action it is an important
antileishmanial drug that has a long half-life and reports of drug resistance have been
recently reported (Cojean, Houze, Haouchine, Huteau, Lariven, Hubert, Michard, Bories,
Pratlong, Le Bras, Loiseau, & Matheron, 2012; Bhandari, Kulshrestha, Deep, Stark,
Prajapati, Ramesh, Sundar, Schonian, Dujardin, & Salotra, 2012) Over a decade of work
has gone into studying lab induced miltefosine resistant promastigotes in anticipation of
the emergence of drug resistance in the field.
The first cell line studied was a multi drug resistant L. tropica line resistant to
daunomycin and miltefosine, which showed, increased expression in the MDR1 gene
(Perez-Victoria, Perez-Victoria, Parodi-Talice, Jimenez, Ravelo, Castanys, & Gamarco,
2001). This codes for a P-glycoprotein ABC transporter that effluxes the drug (Perez-
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Victoria et al., 2001). The mechanism has not been shown to be present in future lines
that are resistant to miltefosine alone. The next line developed was an L. donovani line
cultured with up to 40 µM of miltefosine and has an IC50 around 75 µM (Seifert, Matu,
Perez-Victoria, Castanys, Gamarro, & Croft 2003). Importantly, the resistance phenotype
was maintained in the absence of drug for the 3 months it was monitored (Seifert et al.,
2003) With this line it was found that a transporter named LdMT a P-type ATPase is
responsible for inward translocation of miltefosine and that mutations in this gene were
found in a parasite with a resistant phenotype (Perez-Victoria, Castanys, &Gamarro,
2003). Wild type LdMT was transfected into the miltefosine resistant parasite and
miltefosine sensitivity was restored, proving its involvement in miltefosine resistance in
this line (Perez-Victoria, Gamarro, Ouellette, & Castanys, 2003)
Fatty acid and sterol metabolism was then explored comparing resistant
and sensitive promastigotes (Rakotomanga, Saint-Pierre-Chazalet, & Loiseau, 2005). It
was found that miltefosine resistance affects three lipid biochemical pathways; fatty acid
elongation, the desaturase system responsible for fatty acid alkyl chain unsaturation, and
the C-24-alkylation of sterols (Rakotomanga et al., 2005) It was then found that LdMT
has a beta subunit Ros3 and that both are required to form a functional transporter (PerezVictoria, Sanchez-Canete, Castanys, & Gamarro, 2006). Continuing with the search for
other possible mechanisms of resistance, it was found that when LiABCG4 was
overexpressed, the drug was effluxed, resulting in resistance (Castanys-Munoz, AlderBaerens, Pomorski, Gamarro, & Castanys, 2007). LiABCG4 overexpression has not been
seen in a drug selected resistant parasite. Further characterization of LdMT inactivated
leishmania promastigotes was conduced in vitro using macrophages and in vivo using
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mice (Seifert, Perez-Victoria, Stettler, Sanchez-Canete, Castanys, Gamarro, & Croft,
2007). It was found that when the promastigotes transformed to amastigotes in
macrophages and mice their miltefosine resistant phenotype was maintained.
Proteomic analysis of leishmania resistant to 80 µM of miltefosine showed
differences in levels of eIFA a eukaryotic initiation factor (Singh, Chavan, & Dey, 2008).
Recently, several L. major miltefosine resistant promastigotes have been cloned and their
genomes sequenced (Coelho, Boisvert, Mukherjee, Leprohon, Corbeil, & Ouellette,
2012). This work has shown that when a leishmania culture is exposed to miltefosine
each individual parasite can go under genetic modification independently of its neighbors
due to clonal replication (Coelho et al., 2012). The sequencing of the clones revealed
different mutations in LdMT, pyridoxal kinase, and α-adaptin genes, which resulted in
different IC50 values (Coelho et al., 2012). The culmination of over a decade of work on
miltefosine resistance has shown us that miltefosine resistance is multifactorial and
several mechanisms can be employed to deal with ever increasing drug pressure.
Focus of Study
Miltefosine resistant leishmania cell lines have been developed and published in
several labs using promastigotes. Our lab induced drug resistance in a discontinuous
stepwise manner using the clinically relevant mammalian amastigote form. The literature
shows that miltefosine resistance is complex and multifactorial. We sequenced and
measured expression of genes associated with miltefosine resistance in the literature and
based on drug interactions with our parasites. We also determined the fitness of these
parasites. This body of work is an expansion of what we know about the mechanism(s) of
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miltefosine resistance in leishmania. In the future this work can be used to study clinical
isolates that are beginning to emerge in the field.
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Figure 1.1 Leishmania Life Cycle Leishmaniasis is transmitted by the bite of infected
female phlebotomine sandflies. The sandflies inject the infective stage (i.e.,
promastigotes) from their proboscis during blood meals . Promastigotes that reach
the puncture wound are phagocytized by macrophages
and other types of
mononuclear phagocytic cells. Promastigotes transform in these cells into the tissue
stage of the parasite (i.e., amastigotes) , which multiply by simple division and
proceed to infect other mononuclear phagocytic cells . Parasite, host, and other
factors affect whether the infection becomes symptomatic and whether cutaneous or
visceral leishmaniasis results. Sandflies become infected by ingesting infected cells
during blood meals ( , ). In sandflies, amastigotes transform into promastigotes,
develop in the gut
(in the hindgut for leishmanial organisms in the Viannia
subgenus; in the midgut for organisms in the Leishmania subgenus), and migrate to the
proboscis .
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Table 1.1: Antileishmanial Drugs

	
  

18	
  

List of References
Akopyants, N. S., Kimblin, N., Secundino, N., Patrick, R., Peters, N., Lawyer, P., . . .
Sacks, D. L. (2009). Demonstration of genetic exchange during cyclical
development of leishmania in the sand fly vector. Science, 324(5924), 265-268.
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., . . . den Boer, M.
(2012). Leishmaniasis worldwide and global estimates of its incidence. PloS One,
7(5), e35671.
Arthur, G., & Bittman, R. (1998). The inhibition of cell signaling pathways by antitumor
ether lipids. Biochimica Et Biophysica Acta, 1390(1), 85-102.
Banuls, A. L., Bastien, P., Pomares, C., Arevalo, J., Fisa, R., & Hide, M. (2011). Clinical
pleiomorphism in human leishmaniases, with special mention of asymptomatic
infection. Clinical Microbiology and Infection, 17(10), 1451-1461.
Basselin, M., Denise, H., Coombs, G. H., & Barrett, M. P. (2002). Resistance to
pentamidine in leishmania mexicana involves exclusion of the drug from the
mitochondrion. Antimicrobial Agents and Chemotherapy, 46(12), 3731-3738.
Bhandari, V., Kulshrestha, A., Deep, D. K., Stark, O., Prajapati, V. K., Ramesh, V., . . .
Salotra, P. (2012). Drug susceptibility in leishmania isolates following miltefosine
treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
PLoS Neglected Tropical Diseases, 6(5), e1657.

	
  

19	
  

Bresslau E, Scremin L. (1924). Die kerne der ty-panosomen und ihr verhaltzen zur
nuclealreaktion. Arch Protist 48, 509-515.
Camizotti, L., Yamashiro-Kanashiro, E., & Cotrim, P. C. (2009). Identification and
chromosomal localization of one locus of leishmania (L.) major related with
resistance to itraconazole. Parasitology Research, 105(2), 471-478.
Castanys‐Muñoz, E., Alder‐Baerens, N., Pomorski, T., Gamarro, F., & Castanys, S.
(2007). A novel ATP‐binding cassette transporter from leishmania is involved in
transport of phosphatidylcholine analogues and resistance to alkyl‐phospholipids.
Molecular Microbiology, 64(5), 1141-1153.
Centers for Disease Control and Prevention (2009). DPDx Laboratory identification of
parasites of public health concern-parasites and health: Leishmaniasis. Retreived
from http://dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm.
Chang, K. (1980). Human cutaneous leishmania in a mouse macrophage line:
Propagation and isolation of intracellular parasites. Science, 209(4462), 1240.
Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., . . . Boelaert, M.
(2007). Visceral leishmaniasis: What are the needs for diagnosis, treatment and
control? Nature Reviews Microbiology, 5(11), 873-882.
Charles, C. (1904). Annales De Instate Pasteur De Tunis,

	
  

20	
  

Chawla, B., Jhingran, A., Panigrahi, A., Stuart, K. D., & Madhubala, R. (2011).
Paromomycin affects translation and vesicle-mediated trafficking as revealed by
proteomics of Paromomycin–Susceptible–Resistant leishmania donovani. PloS One,
6(10), e26660.
Christophers, S. R. (1904). A preliminary report on a parasite found in persons suffering
from enlargement of the spleen in india. Office of the Superintendent of Government
Printing, India.
Coelho, A. C., Boisvert, S., Mukherjee, A., Leprohon, P., Corbeil, J., & Ouellette, M.
(2012). Multiple mutations in heterogeneous miltefosine-resistant leishmania major
population as determined by whole genome sequencing. PLoS Neglected Tropical
Diseases, 6(2), e1512.
Coelho, A. C., Gentil, L. G., da Silveira, J. F., & Cotrim, P. C. (2008). Characterization
of Leishmania amazonensis promastigotes resistant to pentamidine. Experimental
Parasitology, 120(1), 98-102.
Cojean, S., Houzé, S., Haouchine, D., Huteau, F., Lariven, S., Hubert, V., . . . Le Bras, J.
(2012). Leishmania resistance to miltefosine associated with genetic marker.
Emerging Infectious Diseases, 18(4), 704-706.
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006). Drug resistance in leishmaniasis.
Clinical Microbiology Reviews, 19(1), 111-126.

	
  

21	
  

Croft, S. L., Seifert, K., & Yardley, V. (2006). Current scenario of drug development for
leishmaniasis. Indian Journal of Medical Research, 123(3), 399.
David, C. V., & Craft, N. (2009). Cutaneous and mucocutaneous leishmaniasis.
Dermatologic Therapy, 22(6), 491-502.
de Souza, W., Attias, M., & Rodrigues, J. C. F. (2009). Particularities of mitochondrial
structure in parasitic protists (apicomplexa and kinetoplastida). The International
Journal of Biochemistry & Cell Biology, 41(10), 2069-2080.
Gupta, S. (2011). Visceral leishmaniasis: Experimental models for drug discovery. The
Indian Journal of Medical Research, 133(1), 27-39.
Ives, A., Ronet, C., Prevel, F., Ruzzante, G., Fuertes-Marraco, S., Schutz, F., . . .
Hickerson, S. M. (2011). Leishmania RNA virus controls the severity of
mucocutaneous leishmaniasis. Science Signalling, 331(6018), 775-778.
James, W. D., Berger, T., & Elston, D. (2011). Andrew's diseases of the skin: Clinical
dermatology Saunders.
Khamesipour, A., Rafati, S., Davoudi, N., Maboudi, F., & Modabber, F. (2006).
Leishmaniasis vaccine candidates for development: A global overview. Indian
Journal of Medical Research, 123(3), 423-438.
Kumari, S., Kumar, A., Samant, M., Singh, N., & Dube, A. (2008). Discovery of novel
vaccine candidates and drug targets against visceral leishmaniasis using proteomics
and transcriptomics. Current Drug Targets, 9(11), 938-947.

	
  

22	
  

Leishman, W. (1903). On the possibility of the occurrence of trypanosomiasis in india.
British Medical Journal, 1(2213), 1252-1254.
McCall, L. I., & Matlashewski, G. (2010). Localization and induction of the A2 virulence
factor in leishmania: Evidence that A2 is a stress response protein. Molecular
Microbiology, 77(2), 518-530.
Melby, P. C., Chandrasekar, B., Zhao, W., & Coe, J. E. (2001). The hamster as a model
of human visceral leishmaniasis: Progressive disease and impaired generation of
nitric oxide in the face of a prominent Th1-like cytokine response. The Journal of
Immunology, 166(3), 1912-1920.
Meleney, H. E. (1925). The histopathology of kala-azar in the hamster, monkey, and
man. American Journal of Pathology, 1(2), 147-168.
Neuber, H. (2008). Leishmaniasen. JDDG: Journal Der Deutschen Dermatologischen
Gesellschaft, 6(9), 754-765.
Pan, A. A. (1984). leishmania mexicana: serial cultivation of intracellular stages in a
cell-free medium. Experimental Parasitology, 58(1), 72-80.
Pérez-Victoria, F. J., Sánchez-Cañete, M. P., Castanys, S., & Gamarro, F. (2006).
Phospholipid translocation and miltefosine potency require both L. donovani
miltefosine transporter and the new protein LdRos3 in leishmania parasites. Journal
of Biological Chemistry, 281(33), 23766-23775.

	
  

23	
  

Pérez-Victoria, F. J., Castanys, S., & Gamarro, F. (2003). Leishmania donovani
resistance to miltefosine involves a defective inward translocation of the drug.
Antimicrobial Agents and Chemotherapy, 47(8), 2397-2403.
Pérez-Victoria, F. J., Gamarro, F., Ouellette, M., & Castanys, S. (2003). Functional
cloning of the miltefosine transporter. Journal of Biological Chemistry, 278(50),
49965-49971.
Pérez-Victoria, J. M., Pérez-Victoria, F. J., Parodi-Talice, A., Jiménez, I. A., Ravelo, A.
G., Castanys, S., & Gamarro, F. (2001). Alkyl-lysophospholipid resistance in
multidrug-resistant leishmania tropica and chemosensitization by a novel Pglycoprotein-like transporter modulator. Antimicrobial Agents and Chemotherapy,
45(9), 2468-2474.
Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., . . . De, T. (2012).
Mechanism of amphotericin B resistance in clinical isolates of leishmania donovani.
Antimicrobial Agents and Chemotherapy, 56(2), 1031-1041.
Rakotomanga, M., Saint-Pierre-Chazalet, M., & Loiseau, P. (2005). Alteration of fatty
acid and sterol metabolism in miltefosine-resistant leishmania donovani
promastigotes and consequences for drug-membrane interactions. Antimicrobial
Agents and Chemotherapy, 49(7), 2677-2686.
Rogers, L. (1904). Preliminary note on the development of trypanosoma in cultures of the
cunningham-leishman-donovan bodies of cachexial fever and kala-azar. The Lancet,
164(4221), 215-216.

	
  

24	
  

Ross, R. (1903). Note on the bodies recently described by leishman and donovan. British
Medical Journal, 2(2237), 1261.
Roy, G., Dumas, C., Sereno, D., Wu, Y., Singh, A. K., Tremblay, M. J., . . .
Papadopoulou, B. (2000). Episomal and stable expression of the luciferase reporter
gene for quantifying Leishmania spp. infections in macrophages and in animal
models. Molecular and Biochemical Parasitology, 110(2), 195-206.
Sacks, D. L., & Perkins, P. V. (1984). Identification of an infective stage of leishmania
promastigotes. Science, 223(4643), 1417-1419.
Seifert, K., Matu, S., Javier Perez-Victoria, F., Castanys, S., Gamarro, F., & Croft, S. L.
(2003). Characterisation of leishmania donovani promastigotes resistant to
hexadecylphosphocholine (miltefosine). International Journal of Antimicrobial
Agents, 22(4), 380-387.
Seifert, K., Pérez-Victoria, F. J., Stettler, M., Sánchez-Cañete, M. P., Castanys, S.,
Gamarro, F., & Croft, S. L. (2007). Inactivation of the miltefosine transporter,
LdMT, causes miltefosine resistance that is conferred to the amastigote stage of
leishmania donovani and persists in vivo. International Journal of Antimicrobial
Agents, 30(3), 229-235.
Selvapandiyan, A., Dey, R., Nylen, S., Duncan, R., Sacks, D., & Nakhasi, H. L. (2009).
Intracellular replication-deficient leishmania donovani induces long lasting
protective immunity against visceral leishmaniasis. The Journal of Immunology,
183(3), 1813-1820.

	
  

25	
  

Sharma, U., & Singh, S. (2008). Insect vectors of leishmania: Distribution, physiology
and their control. Journal of Vector Borne Disease, 45(4), 255-272.
Silvestre, R., Cordeiro-da-Silva, A., & Ouaissi, A. (2008). Live attenuated leishmania
vaccines: A potential strategic alternative. Archivum Immunologiae Et Therapiae
Experimentalis, 56(2), 123-126.
Singh, G., Chavan, H. D., & Dey, C. S. (2008). Proteomic analysis of miltefosineresistant leishmania reveals the possible involvement of eukaryotic initiation factor
4A (eIF4A). International Journal of Antimicrobial Agents, 31(6), 584-586.
Stauber, L. A. (1958). Host resistance to the khartoum strain of leishmania donovani.
Rice Institute Pamphlet, 45, 80-96.
Wheeler, R. J., Gluenz, E., & Gull, K. (2011). The cell cycle of leishmania:
Morphogenetic events and their implications for parasite biology. Molecular
Microbiology, 79(3), 647-662.
World Health Organisation. (2012). Leishmaniasis. Retrieved from
http://www.who.int/leishmaniasis/burden/en/
Zink, A. R., Spigelman, M., Schraut, B., Greenblatt, C. L., Nerlich, A. G., & Donoghue,
H. D. (2006). Leishmaniasis in ancient egypt and upper nubia. Emerging Infectious
Diseases, 12(10), 1616-1617.

	
  

26	
  

Chapter Two:
Derivation and Characterization of MHOM/SD/75/1246/130/ Khartoum (WR 378)
Leishmania donovani Axenic Amastigote Cell Line
Abstract
Leishmania donovani causes a deadly visceral form of leishmaniasis that
predominately plagues some of the poorest and most vulnerable of the world’s
population. Currently, the few drugs we have to treat this deadly disease have severe
toxicity issues and resistance to them is emerging in many areas. Robust drug screening
programs are vital for discovering the next generation of anti-leishmanial drugs. Drugscreening programs could benefit from having a reliable axenic amastigote cell line for
high throughput primary screening of compounds because amastigote data is more
clinically relevant than promastigote data. MHOM/SD/75/1246/130/ Khartoum (WR
378) promastigotes have been used extensively for in vivo hamster studies. Now a stable
axenic amastigote continuous culture has been developed from this line and characterized
in vitro and in vivo to serve as a complement to a visceral leishmaniasis drug-screening
program.
Introduction
Leishmaniasis is caused by a family of leishmania parasites; 30 different species
have been identified that cause various clinical symptoms (Neuber, 2008). Leishmania is
a flagellated protozoan parasite of animals and humans responsible for the presentation of
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leishmaniasis. It has a divalent life cycle consisting of a promastigote form inside a sand
fly vector and an amastigotes form that resides in the parasitopherous vacuole of
macrophages in humans. Leishmania donovani causes a visceral form of leishmaniasis
that is characterized by hepatomegaly and splenomegaly, and results in mortality when
untreated (Chappuis, Sundar, Hailu, Ghalib, Rijal, Peeling, Alvar, & Boelaert, 2007).
Currently, there are 500,000 new cases of visceral leishmaniasis and 50,000 deaths
reported each year (Chappuis et al., 2007). Many current drug therapies to treat
leishmaniasis are toxic, expensive, and developing resistance. There is a need to develop
new safe and cheap drugs to treat this deadly disease.
Two L. donovani, 1S-CL2D and MHOM/SD/75/1246/130/ Khartoum (WR378)
laboratory cell lines have been studied and characterized for over 30 years in the
literature (Dennis, Chapman, Hanson, & Lujan, 1985; Dennis, Lujan, Chapman, &
Hanson, 1986; Berman, Hanson, Lovelace, Waits, Jackson, Chapman, & Klein, 1987;
Berman, Ksionski, Chapman, Waits, & Hanson, 1992; Wang, Zhu, Srivastava, Liu,
Sweat, Pandharkar, Stephens, Riccio, Parman, Munde, Mandal, Madhubala, Tidwell,
Wilson, Boykin, Hall, Kyle, & Werbovetz, 2010; Dwyer, 1977; Debrabant, Joshi,
Pimenta, & Dwyer, 2004). An axenic amastigote cell line has been derived for 1S-CL2D
but not for MHOM/SD/75/1246/130 (Debrabant et al., 2004). The
MHOM/SD/75/1246/130 promastigote cell line has been used extensively for drug
discovery in vivo. However, promastigotes are not useful for primary drug screening
intended for human use due to the stage specific action of drugs. The first line drug
Glucantime is 271 times more effective on amastigotes than promastigotes (Ephros,
Bitnun, Shaked, Waldman, & Ziberstein, 1999). If Glucantime were screened for using a
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promastigote cell line it would have been deemed ineffective. In this paper we describe
the derivation and characterization of a stable continuous axenic amastigote
MHOM/SD/75/1246/130 culture (figure 2.1) in vitro and in vivo for use in a visceral
leishmaniasis drug discovery program.
Materials and Methods
Cell Lines. J774A.1 (ATCC, Manassas, VA) macrophages were cultured in RPMI 1640
(Invitrogen Corp., Carlsbad, CA) at a pH of 7.2 containing 10 % fetal bovine serum
(Invitrogen Corp., Carlsbad, CA) and 1 % penicillin-streptomycin (Invitrogen Corp.,
Carlsbad, CA) The cells were incubated at 37 °C in a humidified atmosphere containing 5
% CO2 and serially passaged biweekly. Peritoneal macrophages harvested from BALB/c
mice were cultured in the same media as the J774 macrophages. L. donovani
MHOM/SD/75/1246/130 promastigotes were incubated at 27 °C and cultured in
Schneider’s Drosophila media at a pH of 7.2 with 1 % penicillin-streptomycin and 20 %
FBS. MHOM/SD/75/1246/130 L. donovani axenic amastigotes were cultured in RPMI
1640 at a pH of 5.5 with 7.5 g/L Hepes (Invitrogen Corp., Carlsbad, CA), 5.86 g/L MES
(Sigma-Aldrich, St Louis, MO), 2 g/L sodium bicarbonate (Fisher Scientific, Pittsburg,
PA), 10 mg/L Hemin (Sigma-Aldrich, St Louis, MO), 100 µM Xanthine (Sigma-Aldrich,
St Louis, MO), 40 mg/L Tween-80 (Sigma-Aldrich, St Louis, MO), 1 % PenicillinStreptomycin, 5 g/L Trypton-Peptone (BD Bioscience, Sparks, MD), and 20 % 16 hours
heat inactivated FBS. L. donovani was incubated at 37 °C. All culturing was done using
vented or non-vented 25 cm2 tissue culture flasks (Coning, Lowell, MA) depending on
CO2 needs.
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Drugs. Sodium stibogluconate, meglumine antimonate, amphotericin B, miltefosine,
sitamaquine, and bisbenzimide H. All were used as standard drugs for cell viability
assays.
Cell Viability Assay. The viability of amastigotes and promastigotes was determined by
the Cell Titer 96 Aqueous Assay (Promega, Madison, WI) that employs a tetrazolium
compound [3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4sulphophenyl)-2H-tetrazolium; MTS] and electron-coupling reagent, phenazine
methosulphate (PMS). Test compounds were serially diluted in 100 µl of PBS in 96 well
plates using a Biomeck 3000 (Beckman Coulter, Miami, FL). Ten µl of each well was
transferred to another 96 well plate and then receives 90 µl of parasites in media. The
parasites were in a concentration to have 66,000 parasites per well. After 72 hours 20 µl
of MTS solution is added to each well in the 96 well plates. The plates were then
incubated at 27 and 37 °C for promastigotes and amastigotes, respectively, for four hours
to achieve optimal color development. After 4 h of incubation, the OD values were
determined at 490 nm using a Spectra Max M2 (Molecular Devices, Sunnyvale, CA). The
results were presented as the percentage of survivors (OD value with test compound
divided by that of untreated control). Curve fitting using non-linear regression was done
using table curve to obtain IC50 values.
Cell Growth Measurements. Using 25 cm2 tissue culture flasks, 1 x 106 promastigotes
or amastigotes per ml were seeded and counted every 24 hours for 4 days using a
hemocytometer (Fisher Scientific, Pittsburg, PA) was used to calculate the culture
density. The average of triplicate time points were used to calculate the growth rate in
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excel using exponential regression formula Y=be*g*x. The doubling time was calculated
by n=ln(2)/g, with g being the growth rate.
Axenic L. donovani Culture Generation. This culture was developed by taking L.
donovani promastigotes and growing them for 8 passages in amastigote media at a pH of
7.2 and 27 °C followed by growing them for 8 passages at 37 °C. During that time, the
pH was gradually reduced to a pH of 5.5. The cultures were split 1:5 every 2 days in 25
cm2 non-vented tissue culture flasks.
In Vitro Macrophage Infections. J774 and peritoneal macrophages were seeded onto 96
well plates at a concentration of 50,000 cells per well. The macrophages were allowed to
adhere over one hour at 37 ºC and 5 % CO2. Cells were washed with warm PBS
following attachment. For parasite infection, L. donovani promastigotes and amastigotes
were added at 10:1, parasite to macrophage ratio. Parasites were allowed to infect
macrophages for an additional 4 hours prior to washing to remove un-phagocytized
parasites and then incubated overnight in macrophage media. Macrophages were
removed by scraping with the tip of a pipet in 100 µl of PBS. The cell suspension was
transferred to the funnel of an E-Z Cytospin (Thermo Scientific, Rochester, NY) and
centrifuged. Cells were attached to an alcohol-washed microscope slide by spinning at
800 RPM for 5 min. The slides air-dried and fixed in methanol, followed by staining
with 20% Geimsa (Fisher Scientific, Pittsburg, PA) for 5 minutes. Then the number of
parasites was counted per 500 macrophages to determine parasite burden at 24, 48, 72,
and 96 hours time points.
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In Vivo Infections. Four week old male Syrian hamsters (Mesocricetus auratus) around
40-60 grams were obtained from Harlan Laboratories (Livermore, CA) and maintained in
a special pathogen free BSL2 facility. Isoflurane (Isothesia, Butler Animal Health
Supply, Dublin, OH) was used to anesthetize the hamsters before infection. Each hamster
received an intracardiac inoculation of 2x108 amastigotes or promastigotes, suspended in
200 µl of amastigote or Schneider’s drosophila media. Care was taken that the needle
stayed in the heart throughout the infection by pulling back the plunger and observing the
backflow of blood halfway through the inoculation. After 11 days the hamsters were
sacrificed by CO2 asphyxiation and liver, spleen, and bone marrow were collected as
described by (Srivastava, Sweat, Azizan, Vesely, & Kyle, 2012). Hamsters were handled
according to local and federal regulations, and the University of South Florida
Institutional Animal Care and Use Committee approved research protocols.
Determination of Parasite Burden in Tissues
Direct Microscopic Examination. A segment of liver and spleen were cut and gently
taped against a glass slide multiple times, fixed with methanol and then stained with 20 %
Geimsa for 5 minutes. Similarly bone marrow was extracted with 100 µl of media and
slid across a glass slide with the tip of another slide to make a thin smear. Parasite burden
is determined by Leishman Donovan Units (LDU), which is calculated as organ mass (g)
multiplied by the number of amastigotes per 500 macrophage nuclei (Stauber, 1958).
DNA Extraction and Real-Time PCR. As described by Srivastava et al., 2012, DNA
extraction was performed using the QIAamp DNA Mini kit (Qiagen, USA). Using this
protocol 80 µl of the homogenized liver, spleen, and bone marrow samples were added to
100 µl of tissue lysis buffer and 20 µl of proteinase K and incubated at 56 °C for 2 hours.
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Then samples were loaded into a QIAcube (Qiagen, USA) for DNA extraction. After
extraction DNA concentration was determined in ng/ul using a NanoDrop 1000
spectrophotometer (Thermo Scientific, Rochester, NY). A real-time hot start PCR was
performed using the Stratagene Brilliant SYBR Green QPCR Master Mix (Strategene, La
Jolla, CA) in a Light Cycler, Stratagene, MX3000P (Strategene, La Jolla, CA). Extracted
genomic DNA (5 µl) was added to 20 µl reaction mixture containing 1x SYBR Green
Master mix, 100 nM each primer (final concentration), 2 µM ROX reference dye (final
concentration) and DNase/RNase free water (Sigma-Aldrich, St. Louis, MO). The
primers used 5’-CCTATTTTTACACCAACCCCCAGT-3’ and reverse, 5’GGTAGGGGCGTTCTGCGAAA-3’ used in this protocol were developed by Nicolas,
Prina, Lang, & Milon, (2002). Known quantities of parasites were added to parasite free
hamster liver tissue and DNA was extracted. MXPro, QPCR software was used to
generate logistic regression analysis of the spiked standards and calculated the number of
parasites within each test sample based on Cq values generated (Srivastava et al. 2012).
RNA Extraction and RT-qPCR. RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA) then treated with DNase. RNA was then quantified using RiboGreen RNA
quantitation reagent (Invitrogen, Carlsbad, CA). RNA extracted was converted to cDNA
using Superscript III (Invitrogen, Carlsbad, CA). A real-time hot start PCR was
performed using the Stratagene Brilliant SYBR Green QPCR Master Mix (Strategene, La
Jolla, CA) in a Light Cycler, Stratagene, MX3000P (Strategene, La Jolla, CA). DNA (5
µl) was added to 20 µl reaction mixture containing 1x SYBR Green Master mix, 20 nM
each primer, 2 µM ROX reference dye (final concentration) and DNase/RNase free water
(Sigma-Aldrich, St. Louis, MO). PCR amplification was performed as follows: 50 °C for
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2 minutes and 95 °C for 10 seconds followed by 40 cycles at 95 °C for 30 seconds, 62 °C
for 1 minute and 72 °C for 20 seconds (Biyani, Mandal, Seth, Saint, Natarajan, Ghosh, &
Madhubala, 2011). Amplification of Glyceraldehyde-3-phosphate dehydrogenease
(GAPDH) was used as an internal control (Biyani et al., 2011). Starting with 50 ng of
cDNA, six 1:10 dilutions were amplified using GAPDH to generate a standard curve
using MxPro, QPCR software. The standard curve generated was Y= -3.361*Log(x)
+43.18 with an efficiency of 98.4% and an R2 of 0.999. The ΔΔCt method was used to
calculate RNA expression. PrimeTime qPCR primers (IDT, Coralville, IA) were used to
measure relative expression of the following genes: LinJ.22.0670 (A2), LinJ.33.0860
(Beta-tubulin), LinJ.30.2990 (Glyceraldehyde 3-phosphate dehydrogenase, glycosomal),
table 2.1.
Results
Axenic amastigote drug sensitivity: Using an MTS assay the IC50 values were
determined for both MHOM/SD/75/1246/130 amastigotes and promastigotes (table 2.2).
The IC50 values between the two stages of the parasite are substantially different for some
standard drugs. It has been observed that the different stages of the parasite have varying
susceptibilities to standard drugs (Vermeersch, Luz, Tote, Timmermans, Cos, & Maes,
2009).
Gene Expression. Using RT-qPCR we show that the amastigote specific A2 gene,
LinJ.22.0670, is expressed exclusively by MHOM/SD/75/1246/130 axenic amastigotes
and not MHOM/SD/75/1246/130 promastigotes (figure 2.2). This relative expression of
the A2 was found in three separate axenic amastigote samples and none of the
promastigotes. However, they had equal expression of GADPH. Beta-tubulin and
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Glyceraldehyde 3-phosphate dehydrogenase, glycosomal both had higher relative
expression in promastigotes compared to amastigotes. Similarly, increased promastigote
expressions of several genes including Beta-tubulin and Glyceraldehyde 3-phosphate
dehydrogenase, glycosomal, have been reported (Leifso, Cohen-Freue, Dogra, Murry, &
McMaster, 2007).
Cell Growth Measurements. The growth rate of amastigotes and promastigotes are
shown in figures 2.3. The doubling time of the log phase axenic amastigotes is 27.1±1.2
hours. The promastigotes have a doubling time of 24.1±1 hours. In both cases the time
points were taken every 24 hours for 4 days.
Infected Macrophage Model. J774 and mouse peritoneal macrophages were both
susceptible to infection by MHOM/SD/75/1246/130 promastigotes and amastigotes
(figures 2.4 & 2.5). In figures 2.6 and 2.7 it is clear that promastigotes and amastigotes
can produce robust infections in J774 and mouse peritoneal macrophages respectively.
The parasite numbers for both the amastigotes and promastigotes steadily increased at the
24, 48, 72, and 96-hour time points. The amastigotes had a dramatically higher parasite
burden in both the J774 and mouse peritoneal macrophages.
In Vivo Hamster Model. Both promastigotes and amastigotes gave a robust infection in
the golden hamster that predominately congregates in the liver, spleen, and bone marrow
(figure 2.8). However, when using 2 x108 parasites per hamster, the parasite burden is 20
% greater in hamsters infected with amastigotes versus promastigotes (figure 2.9). This
observation is consistent for parasite quantity in the liver, spleen, and bone marrow as
determined by impression smears and Real-Time PCR.
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Discussion
The Khartoum strain of promastigotes has been demonstrated to produce a fatal
infection in 169 days in the hamster (Stauber, 1958). For decades this strain has been
used to infect golden hamsters for the purpose of testing compounds to treat visceral
leishmaniasis (Berman et al., 1987). Amastigotes have been cultivated from hamsters
spleens infected with promastigotes of MHOM/SD/75/1246/130, but until now there has
never been an axenic amastigote cell line of the MHOM/SD/75/1246/130 to use in a
visceral leishmaniasis drug discovery program. The differences in drug susceptibility
between leishmania species and even strains of L. donovani can be substantial (MoraisTeixeira, Damasceno, Galuppo, Romanha, & Rabello, 2011). Therefore, it is beneficial to
have the option of using a single strain for a drug discovery program to make
interpretation of results less variable.
We developed an axenic amastigote MHOM/SD/75/1246/130 cell line and
characterized it as an amastigote, based upon morphology and gene expression. As seen
in figure 2.1 the amastigote has an oval shape with no visible flagellum compared to the
classic leptomona morphology of promastigotes, from which the amastigotes were
derived. The axenic amastigotes also expressed the amastigote specific A2 gene, and
expressed less Beta-tubulin and Glyceraldehyde 3-phosphate dehydrogenase, glycosomal
than its promastigote parent line. Based on morphology and gene expression we believe
we developed a true axenic amastigote and not an intermediate stage.
Promastigotes and axenic amastigotes are both easy to culture quickly in mass
quantities, which makes them ideal candidates for primary screening of compounds
before the more clinically relevant, yet labor intensive, in vitro infected macrophage
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model. The differences in IC50 values between promastigotes and amastigotes for some
standard drugs are remarkable. The most poignant example in table 2.2 is meglumine
antimoniate. In a drug screen starting as high as 500 µM meglumine antimoniate was
found to be unreactive to promastigotes while it was found to be active on amastigotes of
the exact same strain of leishmania. With such great stage specific differences in IC50
values between promastigotes and amastigotes (table 2.2), use of the axenic culture for
primary drug screening in lieu of promastigotes would be more clinically relevant.
One of the main attractions for using promastigote and axenic amastigote cultures
for primary screening is that they can both be grown in large numbers relatively quickly.
The log phase promastigotes have a faster doubling time than the axenic amastigotes.
However, with promastigotes it can take weeks to get through the log-phase and have a
uniform culture of stationary metacyclic promastigotes, which are more infective than log
phase promastigotes (Giannini, 1974). This axenic amastigote cell line grows rapidly and
the population has one phase, which makes it ideal for high throughput screening of
compounds for drug discovery. Using a uniform phase of parasites provides less
variability when measuring IC50 values. Therefore, using axenic amastigotes instead of
promastigotes can save weeks of preparation of cultures for drug screening.
In the infected macrophage assay when the same numbers of metacyclic
promastigotes and axenic amastigotes are used to infect either J774 or mouse peritoneal
macrophages the infection by the axenic amastigotes is nearly double that of the
promastigotes (figures 2.4 & 2.5). Both promastigotes and axenic amastigotes have a
steady increase in intra-cellular amastigotes per 24-hour time point. This is significant
because there are examples where leishmania parasites begin to taper off their
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proliferation over time (Mendez, Nell, & Alunda, 1996). The steady increase in
intracellular amastigotes up to 96 hours in the tractable J774 macrophage cell line makes
this a great model for secondary screening of potential anti-leishmanial drugs. These
cultures were only given 4 hours to infect the macrophages before being washed three
times with PBS. There is a greater number of intra-cellular amastigotes per 500
macrophages generated from the axenic amastigotes in comparison to the promastigotes.
Perhaps the promastigotes took time to convert to amastigotes after engulfment before
proliferation, while the axenic amastigotes were able to begin proliferation after
engulfment without a transformation step. Others have found that macrophages can be 4fold more susceptible to axenic amastigotes versus promastigotes (Wenzel, Bank,
Florian, Forster, Zimara, Steinacker, Klinger, Reiling, Ritter, & van Zandbergen, 2011,
Debrabant et al., 2004).
For decades, MHOM/SD/75/1246/130 promastigotes have been used successfully
to infect hamsters, providing good infection in the liver spleen and bone marrow
(Hanson, Chapman, & Kinnamon, 1977). The hamster model that has been used is an 11day model modified from the 8-day hamster model (Stauber, Franchino, & Grun, 1958).
A total of 2x108 parasites are injected into the heart to provide a robust infection that
provides a good model for in vivo drug studies (Stauber et al.,1958). When these
hamsters were injected with the same number of amastigotes, the parasite burden was
about 20 % greater in the amastigote-infected hamsters versus the promastigote-infected
hamsters (figure 2.8).
This paper is the first example of successfully transforming
MHOM/SD/75/1246/130 promastigotes into a stable continuous axenic amastigote
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culture. It is the second L. donovani axenic amastigote line generated after the 1S-CL2D
line (Debrabent et al., 2004). The 1S-CL2D line requires CO2 while the
MHOM/SD/75/1246/130 does not. Also, our line is the first L. donovani line to be used
to characterize differences in drug susceptibility of standard antileishmanial drugs
between promastiotes and axenic amastigotes of the same strain. This culture will
provide the option to use a single parasite strain for a drug discovery pipeline from
primary screening to hamster model screening. The rapidity in which these axenic
amastigotes grow also makes them an asset for studying induction of drug resistance for
L. donovani that is more clinically relevant than promastigote drug resistance lines that
have been generated.
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Table	
  2.1:	
  RT-‐qPCR	
  Primers	
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Table 2.2: Standard Anti-leishmanial Drugs
Compound	
  
Miltefosine	
  
Amphotericin	
  B	
  
Sodium	
  
stibogluconate	
  
Meglumine	
  
antimoniate	
  
Bisbenzimide	
  H	
  
Sitamaquine	
  

Promastigotes	
  
5.42	
  ±	
  0.42	
  
0.6	
  	
  ±	
  0.06	
  

Amastigotes	
  
3.26	
  	
  ±	
  0.11	
  
1.2	
  	
  ±	
  0.09	
  

274	
  	
  ±	
  4.2	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
>500	
  
56.85	
  ±	
  1.2	
  
36.5	
  	
  ±	
  1.1	
  

177.5	
  	
  ±	
  1.3	
  
221.3	
  	
  ±	
  3.1	
  
62.3	
  	
  ±	
  1.6	
  
54.7	
  	
  ±0.7	
  

In vitro IC50 values for promastigotes and amastigotes exposed to standard drugs for 72
hours. Measurements were taken in triplicate and measured in µM.
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Figure 2.1: MHOM/SD/75/1246/130 DAPI images
On the left is a promastigote and on the right is an axenic amastigote. Both were stained with
DAPI and imaged at 100x

.
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Figure	
  2.2:	
  	
  Relative	
  Gene	
  Expression	
  	
  	
  	
  	
  	
  	
  	
  	
  
Relative gene expression of LinJ.22.0670 (A2), LinJ.33.0860 (Beta-tubulin),
LinJ.30.2990 (Glyceraldehyde 3-phosphate dehydrogenase, glycosomal) gene by qRTPCR in triplicate. Measurements were taken in triplicate and the error bars denote
standard deviation. Student t-test determined statistical significance, *p=0.007,
**p=0.005.
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Figure 2.3: MHOM/SD/75/1246/130 Doubling Time
MHOM/SD/75/1246/130 promastigote and amastigote growth over every 24 hours over
4 days. Error bars denote the standard deviation of results taken in triplicate. Growth
rate is determined using exponential regression and doubling time is determined using
ln2/growth rate. Measurements were taken in triplicate and the error bars denote
standard deviation. Student t-test determined statistical significance between doubling
times, p=0.01.
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Figure 2.4: J774 Macrophages Infected by MHOM/SD/75/1246/130, In Vitro
In vitro infectivity of J774 macrophages by leishmania donovani amastigotes and
promastigotes over 24 hour time points. Results are presented as the number of parasites
per 500 macrophages counted. Measurements were taken in triplicate and the error bars
denote standard deviation. Student t-test determined statistical significance, *p=0.001,
**p=0.006, ***p=0.006, ****p=0.02.
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Figure 2.5: Mouse Peritoneal Macrophages Infected by MHOM/SD/75/1246/130
In vitro infectivity of mouse peritoneal macrophages by leishmania donovani
amastigotes and promastigotes over 24 hour time points. Results are presented as the
number of parasites counted per 500 macrophages counted. Measurements were taken
in triplicate and the error bars denote standard deviation. Student t-test determined
statistical significance, , *p=0.002, **p=0.003, ***p=0.005, ****p=0.002.
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Figure 2.6: MHOM/SD/75/1246/130 Infected J774 Macrophages
On the left a J774 macrophage is infected by axenic amastigotes. On the right a J774
macrophage is infected by promastigotes. The pictures are at 100x and the slides are
stained with 20 % Geimsa for 5 minutes.
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Figure 2.7: MHOM/SD/75/1246/130 Infected Mouse Peritoneal Macrophages
On the left a mouse peritoneal macrophage is infected by axenic amastigotes. On the
right a BALB/c mouse peritoneal macrophage is infected by promastigotes. The pictures
are at 100x and the slides are stained with 20 % Geimsa for 5 minutes.
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Figure 2.8: MHOM/SD/75/1246/130 Infected Hamster Tissue
In vivo infectivity of hamster liver by leishmania donovani amastigotes and
promastigotes. Parasite burden was calculated by LDU method for impression smears
and by real time PCR. Measurements were taken in triplicate and the error bars denote
standard deviation. Student t-test determined statistical significance, *p=0.02,
**p=0.007.
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Figure 2.9: MHOM/SD/75/1246/130 Infected Hamster Liver Image
On the left is hamster liver infected by axenic amastigotes. On the right is
hamster liver infected by promastigotes. The pictures are at 100x and the slides
are stained with 20 % Geimsa for 5 minutes.
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Chapter Three:
Selection and Characterization of Miltefosine Resistant Leishmania donovani Axenic
Amastigote Cell Line
Abstract
Miltefosine (Milt) is currently the only oral drug on the market to treat visceral
leishmaniasis and Milt resistance has been recently reported in India. In an effort to
further understand Milt resistance, we used a new axenic amastigote line of L. donovani
to generate a stable, high-grade drug resistant line and to characterize the resistance
genotype(s) and phenotype(s) in vitro and in vivo. We applied discontinuous step-wise
drug pressure to L. donovani axenic amastigotes in vitro to generate a stable Milt
resistance phenotype. The resultant Milt resistant parasite (Milt-R) and its sensitive
parent (Milt-S) were then studied for susceptibility to standard anti-leishmanial drugs in
vitro in two models; Axenic culture and amastigote-infected macrophages. In vivo,
efficacy of Milt treatment of Milt-R and Milt-S lines was determined in hamsters. A
stable drug resistant parasite Milt-R line was generated that expressed 50 fold higher IC50
for Milt-R as compared to Milt-S; this expressed resistance was stable for 12 months
following removal of drug pressure. The Milt resistant phenotype was observed in both
the infected macrophage (62-fold) and in the infected hamster model. In vivo Milt-S
parasite burden was reduced 85 and 95 % in hamsters treated for 5 days with 30 and 50
mg/kg of Milt, respectively. In comparison, for Milt-R infected hamsters, parasite burden

	
  

55	
  

was reduced by only 40 % at the maximal tolerated dose (50 mg/kg Milt) and was not
affected at all by 30 mg/kg Milt. Additionally, candidate genes associated with resistance
were sequenced in Milt-S and -R clones. Mutations that resulted in amino acid changes
were found in the following genes: LdMT, pyridoxal kinase, and α-adaptin. The results of
our studies provide important new information and reagents to elucidate the
mechanism(s) of Milt drug resistance in L. donovani.
Introduction
Leishmania donovani is the causative agent for the devastating disease, visceral
leishmaniasis. The visceral form of leishmaniasis is characterized by
hepatosplenomegaly, and results in mortality when untreated (Chappuis, Sundar, Hailu,
Ghalib, Rijal, Peeling, Alvar, & Boelaert, 2007). Currently, there are 500,000 new cases
of visceral leishmaniasis and 50,000 deaths reported each year (Chappuis et al., 2007).
The rejected cancer drug miltefosine is the first and only oral drug on the market for the
treatment of visceral leishmaniasis. Miltefosine is an alkyl-lysophospholipid and its
mechanism of action on leishmania is poorly understood. Miltefosine is reported to
induce apoptosis and inhibit phosphatidyl choline synthesis (Arthur & Bittman, 1998).
Despite an unclear understanding of its mechanism of action it is an important
antileishmanial drug that has a long half-life. Cases of drug resistance have been recently
reported (Cojean, Houze, Haouchine, Huteau, Lariven, Hubert, Michard, Bories,
Pratlong, Le Bras, Loiseau, & Matheron, 2012; Bhandari, Kulshrestha, Deep, Stark,
Prajapati, Ramesh, Sundar, Schonian, Dujardin, & Salotra, 2012). Over a decade of work
has gone into studying lab induced miltefosine resistant promastigotes in anticipation of
the emergence of drug resistance in the field (Perez-Victoria, Perez-Victoria, Parodi-
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Talice, Jimenez, Ravelo, Castanys, & Gamarco, 2001; Seifert, Matu, Perez-Victoria,
Castanys, Gamarro, & Croft, 2003; Perez-Victoria, Castanys, &Gamarro, 2003; PerezVictoria, Gamarro, Ouellette, & Castanys, 2003; Rakotomanga, Saint-Pierre-Chazalet, &
Loiseau, 2005; Perez-Victoria, Sanchez-Canete, Castanys, & Gamarro, 2005; CastanysMunoz, Alder-Baerens, Pomorski, Gamarro, & Castanys, 2007; Seifert, Perez-Victoria,
Stettler, Sanchez-Canete, Castanys, Gamarro, & Croft, 2007; Singh, Chavan, & Dey,
2008; Coelho, Boisvert, Mukherjee, Leprohon, Corbeil, & Ouellette, 2012).
The first cell line studied was a multi drug resistant L. tropica line resistant to
daunomycin and miltefosine, which showed increased expression in the MDR1 gene,
which codes for a P-glycoprotein ABC transporter that effluxes the drug (Perez-Victoria,
et al., 2001). The mechanism has not been shown to be present in future lines that are
resistant to miltefosine alone. The next line developed was an L. donovani line cultured
with up to 40 µM of miltefosine and had an IC50 around 75 µM (Seifert et al., 2003).
Importantly, the resistance phenotype was maintained in the absence of drug for the 3
months it was monitored. With this line it was found that a transporter named LdMT a Ptype ATPase is responsible for inward translocation of miltefosine and mutations in this
gene were found in a resistant phenotype (Perez-Victoria et al., 2003). Wild type LdMT
was transfected into the miltefosine resistant parasite and miltefosine sensitivity was
restored, proving its involvement in miltefosine resistance in this line (Perez-Victoria et
al., 2003).
Fatty acid and sterol metabolism was then explored comparing resistant
and sensitive promastigotes (Rakotomanga, et al., 2005). It was found that miltefosine
resistance affects three lipid biochemical pathways: Fatty acid elongation, the desaturase
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system responsible for fatty acid alkyl chain unsaturation, and the C-24-alkylation of
sterols (Rakotomanga et al., 2005). It was then found that LdMT has a beta subunit Ros3
and both are required to form a functional transporter (Perez-Victoria, et al., 2006).
Continuing with the search for other possible mechanisms of resistance it was found that
when LiABCG4 was overexpressed, miltefosine effluxes resulting in resistance
(Castanys-Munoz et al., 2007). LiABCG4 overexpression has yet to be shown in a drug
selected resistant parasite. Further characterization of LdMT inactivated leishmania
promastigotes was conduced in vitro using macrophages and in vivo using mice (Seifert
et al., 2007). It was found that when the promastigotes transformed to amastigotes in
macrophages and mice their miltefosine resistant phenotype was maintained.
Proteomic analysis of 80 µM miltefosine resistant leishmania showed differences
in levels of eIFA a eukaryotic initiation factor (Singh et al., 2008). Recently several L.
major miltefosine resistant promastigotes have been cloned and their genomes sequenced
(Coelho et al., 2012). This work has shown that when a leishmania culture is exposed to
miltefosine each individual parasite can go under genetic modification independently of
its neighbors due to clonal replication (Coelho et al., 2012). The sequencing of the clones
revealed different mutations in LdMT, pyridoxal kinase, and α-adaptin genes, which
resulted in different IC50 values (Coelho et al., 2012). The culmination of over a decade
of work on miltefosine resistance has suggested that it is multifactorial and that several
mechanisms can be employed to deal with ever increasing drug pressure. Most of the
work has been done with species other than L. donovani and with promastigotes instead
of the amastigotes that infect macrophages. Using stepwise discontinuous drug pressure
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we are the first to report the selection of miltefosine resistance in an axenic amastigote L.
donovani cell line and its characterization in vitro and in vivo.
Materials and Methods
Cell Lines. J774 A.1 (ATCC, Manassas, VA) macrophages were cultured in RPMI 1640
(Invitrogen Corp., Carlsbad, CA) at a pH of 7.2 containing 10 % fetal bovine serum
(Invitrogen Corp., Carlsbad, CA) and 1 % Penicillin-Streptomycin (Invitrogen Corp.,
Carlsbad, CA) The cells were incubated at 37 °C in a humidified atmosphere containing 5
%, CO2 and serially passaged biweekly. Peritoneal macrophages harvested from BALB/c
mice were cultured in the same media as the J774 macrophages. MHOM/SD/75/1246/130
L. donovani axenic amastigotes were cultured in RPMI 1640 at a pH of 5.5 with 7.5 g/L
Hepes (Invitrogen Corp., Carlsbad, CA), 5.86 g/L MES (Sigma-Aldrich, St Louis, MO),
2 g/L sodium bicarbonate (Fisher Scientific, Pittsburg, PA), 10 mg/L Hemin (SigmaAldrich, St Louis, MO), 100 µM Xanthine (Sigma-Aldrich, St Louis, MO), 40 mg/L
Tween-80 (Sigma-Aldrich, St Louis, MO), 1 % Penicillin-Streptomycin, 5 g/L TryptonPeptone (BD Bioscience, Sparks, MD), and 20 % 16 hours heat inactivated FBS. L.
donovani was incubated at 37 °C. All culturing was done using vented or non-vented 25
cm2 tissue culture flasks (Coning, Lowell, MA) depending on CO2 needs.
Induction of Resistance. MHOM/SD/75/1246/130 L. donovani axenic amastigotes were
exposed to increasing stepwise drug pressure to induce resistance. The parasite were
initially put under one µg/ml of miltefosine pressure for four days followed by three days
off pressure. Each successive week the drug pressure was increased by one µg/ml. A final
drug pressure of 12 µg/ml was achieved before the cell line was allowed to grow off
pressure for eight weeks to determine stability of drug resistant phenotype.
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Clones. MHOM/SD/75/1246/130 L. donovani sensitive and resistant parasites were
cloned by serial dilution followed by laser capture micro dissection. These clones were
used for all further studies.
Cell Viability Assay. The viability of amastigotes was determined by the Cell Titer 96
Aqueous Assay (Promega, Madison, WI) that employs a tetrazolium compound [3-(4,5dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium;
MTS] and electron-coupling reagent, phenazine methosulphate (PMS). Test compounds
were serially diluted in 100 µl of PBS in 96 well plates using a Biomeck 3000 (Beckman
Coulter, Miami, FL). Ten µl of each well was transferred to another 96 well plate and
then receives 90 µl of parasites in media. The parasites were in a concentration to have
66,000 parasites per well. After 72 hours 20 µl of MTS solution is added to each well in
the 96 well plates. The plates were then incubated at 27 and 37 °C for promastigotes and
amastigotes, respectively, for four hours to achieve optimal color development. After 4 h
of incubation, the OD values were determined at 490 nm using a Spectra Max M2
(Molecular Devices, Sunnyvale, CA). The results were presented as the percentage of
survivors (OD value with test compound divided by that of untreated control). Curve
fitting using non-linear regression was done using table curve to obtain IC50 values.
Cell Growth and Stress Response. A total of 1 x 106 amastigotes per ml were seeded in
25 cm2 tissue culture flasks and every 24 hours for 5 days a hemocytometer (Fisher
Scientific, Pittsburg, PA) was used to calculate the culture density. The average of
triplicate time points were used to calculate the growth rate is excel using exponential
regression formula Y=be*g*x. The doubling time was calculated by n=ln(2)/g, with g
being the growth rate. The growth rates of the cultures were measured under stress by
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heat and hydrogen peroxide. Heat stress tested was 38 and 39 °C, while hydrogen
peroxide stress was tested for 30 minutes at 0.01 and 0.001 percent.
In Vitro Macrophage Infections. J774 and peritoneal macrophages were seeded onto 96
well plates at a concentration of 50,000 cells per well. The macrophages were allowed to
adhere over one hour at 37 ºC and 5 % CO2. Cells were washed with warm PBS
following attachment. For parasite infection, L. donovani amastigotes were added at 10:1,
parasite to macrophage ratio. Parasites were allowed to infect macrophages for an
additional 4 hours prior to washing to remove un-phagocytized parasites. Macrophages
were removed by scraping with the tip of a pipet in 100 µl of PBS. The cell suspension
was transferred to the funnel of an E-Z Cytospin (Thermo Scientific, Rochester, NY) and
centrifuged. Cells were attached to an alcohol-washed microscope slide by spinning at
800 RPM for 5 min. The slides air-dried and fixed in methanol, followed by staining
with 20 % Geimsa (Fisher Scientific, Pittsburg, PA) for 5 minutes. Then the number of
parasites was counted per 500 macrophages to determine parasite burden at 24, 48, 72,
and 96 hours time points.
In Vivo Infections. Four week old male Syrian hamsters (Mesocricetus auratus) around
40-60 grams were obtained from Harlan Laboratories (Livermore, CA) and maintained in
a special pathogen free BSL2 facility. Isoflurane (Isothesia, Butler Animal Health
Supply, Dublin, OH) was used to anesthetize the hamsters before infection. Each hamster
received an intracardiac inoculation of 2x108 amastigotes, suspended in 200 µl of
amastigote media. Care was taken that the needle stayed in the heart throughout the
infection by pulling back the plunger and observing the backflow of blood halfway
through the inoculation. After 11 days the hamsters were sacrificed by CO2 asphyxiation
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and liver, spleen, and bone marrow were collected as described by (Srivastava et al.,
2012). Hamsters were handled according to local and federal regulations, and the
University of South Florida Institutional Animal Care and Use Committee approved
research protocols.
DNA Extraction. DNA extraction was performed using the QIAamp DNA Mini kit
(Qiagen, USA). Using this protocol 80 µl of the homogenized liver, spleen, and bone
marrow samples or 2x107 parasites from culture were centrifuged and resuspended in 80
µl of PBS and were added to 100 µl of tissue lysis buffer and 20 µl of proteinase K and
incubated at 56 °C for 2 hours. Then samples were loaded into a QIAcube (Qiagen, USA)
for DNA extraction. After extraction, DNA concentration was determined in ng/µl using
a NanoDrop 1000 spectrophotometer (Thermo Scientific, Rochester, NY).
Determination of parasite burden in tissues
Direct microscopic examinations. Impression smears of liver and spleen were made on
glass slides, the tissue was fixed with methanol and then stained with 20 % Geimsa for 5
minutes. Similarly bone marrow was extracted with 100 µl of media and distributed
across a glass slide with the tip of another slide to make a thin smear. Parasite burden is
determined by Leishman Donovan Units (LDU), which is calculated as organ mass (g)
multiplied by the number of amastigotes per 500 macrophage nuclei (Stauber, 1958).
Real-Time PCR. A real-time hot start PCR was performed using the Stratagene Brilliant
SYBR Green QPCR Master Mix (Strategene, La Jolla CA) in a Light Cycler, Stratagene,
MX3000P (Strategene, La Jolla CA). Extracted genomic DNA (5 µl) was added to 20 µl
reaction mixture containing 1x SYBR Green Master mix, 100 nM each primer (final
concentration), 2 µM ROX reference dye (final concentration) and DNase/RNase free
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water (Sigma-Aldrich, St. Louis, MO). The primers used 5’CCTATTTTTACACCAACCCCCAGT-3’ and reverse, 5’GGTAGGGGCGTTCTGCGAAA-3’ used in this protocol were developed by Nicolas,
Prina, Lang, & Milon, (2002). Known quantities of parasites were added to parasite free
hamster liver tissue and DNA was extracted. MxPro. QPCR software was used to
generate logistic regression analysis of the spiked standards to calculate the number of
parasites within each test sample based on Cq values generated (Srivastava et. al., 2012).
RNA Extraction and RT-qPCR. RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA) then treated with DNase. RNA was then quantified using RiboGreen RNA
quantitation reagent (Invitrogen, Carlsbad, CA). RNA extracted was converted to cDNA
using Superscript III (Invitrogen, Carlsbad, CA). A real-time hot start PCR was
performed using the Stratagene Brilliant SYBR Green QPCR Master Mix (Strategene, La
Jolla, CA) in a Light Cycler, Stratagene, MX3000P (Strategene, La Jolla CA). DNA (5
µl) was added to 20 µl reaction mixture containing 1x SYBR Green Master mix, 20 nM
each primer, 2 µM ROX reference dye (final concentration) and DNase/RNase free water
(Sigma-Aldrich, St. Louis, MO). PCR amplification was performed as follows; 50 °C for
2 minutes and 95 °C for 10 seconds followed by 40 cycles at 95 °C for 30 seconds, 62 °C
for 1 minute and 72 °C for 20 seconds (Biyani, Mandal, Seth, Saint, Natarajan, Ghosh, &
Madhubala, 2011).

Amplification of Glyceraldehyde-3-phosphate dehydrogenease

(GAPDH) was used as an internal control (Biyani et al., 2011). Starting with 5 ng of
cDNA, six 1:10 dilutions were amplified using GAPDH to generate a standard curve
using MxPro 3000, QPCR software. The standard curve generated was Y= 3.219*Log(x)*42.97 with an efficiency of 104.5% and an R2 of 0.999. The ΔΔCt method
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was used to calculate RNA expression of genes using primers found in table 3.4.
Sequencing. Polymerase Chain Reaction was performed using 50 µl samples with 31.5
µl DNase free water, 10 µl 5x HF buffer, 1 µl 10 µM DNTPs, 2.5 µl 10 µM primer A, 2.5
µl 10 µM primer B, 0.5 µl Phusion Taq polymerase, and 2 µl template DNA. A hot start
PCR was run using a thermo cycler with the following cycles: 1cycle 98 °C-30 seconds,
32 cycles 98 °C-10 seconds, melting temp-30 seconds, 72 °C-elongation time, and 1
cycle at 72 °C-7 minutes, followed by a final hold at 4 °C. PCR products were tested for
band size using a 1 % agarose gel with a 1kb plus ladder (Invitrogen Corp., Carlsbad,
CA). Primers from IDT (Coralville, IA) used with melting temp and elongation time are
in table 3.2.
Sequencing of PCR products was done by Genewiz (South Plainfield, NJ). PCR
products were first purified using a wizard® SV gel and PCR cleanup system from
Promega (Fitchburg, WI). Then 10 µl of purified PCR product and DNase/RNase free
water were mixed with 5 µl of 5 µM primer and then mailed to Genewiz. Sequencing
Primers from IDT (Coralville, IA) were designed to walk across the template every 500
bases both forward and reverse. Sequencing results from Genewiz were made into single
contigs using CAP3 sequence assembly Program (Huang, X. and Madan, A). Alignment
of sequences was done using A plasmid Editor universal software (ApE). Also amino
acid sequences of contigs was determined using ExPASy translate tool (ExPASy,
University of Geneva, Switzerland)
Pyrosequencing. Pyrosequencing primers were designed using Biotope Pyrosequencing
Assay Design software (Charlottesville, VA) to amplify SNP-containing genes. Primer
sequences and SNP locations are listed in table 3.4. A 5’ biotin label was added to the
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PCR primer running in the opposite direction of the sequencing primer. Sequencing
primer (0.6 µM) diluted in annealing buffer (Biotope, Charlottesville, VA) and 40 µl of
mixture was aliquoted in a 96-well PSQ plate. Binding reaction mixture consisted of 4 µl
of Streptavidin coated Sepharose beads (GE Healthcare) and 51 µl of binding buffer. In
each well of a 96 well plate, 55 µl of binding mixture was added to 25 µl of PCR product
and mixed at 14,000 rpm for 10 minutes. Using the Vacuum Prep Workstation (Biotope,
Charlottesville, VA) the Sepharose-bound PCR products were captured with the Vacuum
Prep Tool immediately after being mixed and washed as follows: 70 % ethanol for 10
seconds, denaturing buffer (0.2 M NaOH) for 10 seconds, and washing buffer (10 mM
Tris-acetate, pH 7.6) for 15 seconds. The vacuum was released and the Sepharose-bound
PCR products were released into the PSQ plate containing sequencing primer. The plate
was incubated at 80 °C for 2 minutes and allowed to cool to room temperature. Plates
were read using a PyroMark ID (Biotope, Charlottesville, VA) in AQ mode using
PyroMarkGold Q96 reagent kit (Qiagen, USA). Assays were completed 3 times for each
DNA template and the average percentage of wild-type allele was plotted over time.
Plasmid Transfection. The entire mutated pyridoxal kinase gene was synthesized and
inserted in a pIDTSMART Amp Blunt plasmid cloning vector (IDT, Coralville, IA). The
plasmid was transformed in electromax DH10BTM electrocompetent E. coli (Invitrogen
Corp., Carlsbad, CA). The DH10BTM were thawed on ice and 20 µl of cells were mixed
with 1 µl of 50 ng/µl plasmid in a chilled centrifuge tube. The mixture was added to a
chilled 0.1-cm cuvette and electroporated with a Bio-Rad GenePulser® II electroporator
at 2.0 kV, 200 Ω, and 25 µF. The electroporated mixture was recovered with one ml of
S.O.C media (Invitrogen Corp., Carlsbad, CA) and transferred to a 15-ml FalconTM tube
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and shacked at 225 rpm at 37 oC for one hour. The cells then diluted 1:100 and spread
over LB plates with 100 µg/ml ampicillin and incubated overnight at 37 oC. Then a single
colony was selected and grown up in LB broth for extraction with a plasmid midi kit
(Qiagen, USA). 2x108 Milt-S axenic amastigotes were transfected with 20 µg of plasmid
in a chilled 0.4-cm cuvette and electroporated with a Bio-Rad GenePulser® II
electroporator at 450 V, ∞ Ω, and 750 µF (Sereno, Roy, Lemesre, Papadopoulou, &
Ouellette, 2001) Transfection of plasmid was confirmed by PCR of the plasmid with
forward primer 5’-CCG GCG CCA TTC TAT CCG CT-3’ and reverse primer 5’-GTG
ACG AAC GTG TAC ATC GAC TGA-3’.
Protein Homology Modeling. Amino acid sequences of pyridoxal kinase were aligned
using ClustalW2. Protein homology models were generated by Swiss-Model using
human pyridoxal kinase’s structure as the reference model (Arnold, Bordoli, Kopp, &
Schwede, 2006; Kiefer, Arnold, Kunzli, Bordoli, & Schwede, 2009; Peitsch, 1995).
Models generated were viewed and annotated using Discovery Studio Visualizer
(Accelrys, San Diego, CA).
Griess Reagent. Nitrate (NO2) production of 50,000 J774 macrophages was evaluated
with macrophages infected with and with out miltefosine sensitive and resistant L.
donovani. Infected macrophages were exposed to a 1:2 stepwise dilution of miltefosine
with a 100 µg/ml starting concentration for 12 dilutions. The macrophages were first
allowed to adhere over one hour at 37 ºC and 5 % CO2 in a 96 well assay plate. Cells were
washed with warm PBS following attachment. For parasite infection, L. donovani
amastigotes were added at a 10:1, parasite to macrophage ratio. Parasites were allowed to
infect macrophages for an additional 4 hours prior to washing to remove un-phagocytized
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parasites. Then dilutions of miltefosine in macrophages media was applied to the plate
with the infected macrophages were allowed to incubate for 24 hours.
After 24 hours, 150 µl supernatants were incubated with 20 µl of Griess reagent (1
% sulphanilamide/0.1 % N-1-naphthylethylene diamine dihydrochloride/2.5 % HCPO4)
and 130 µl of deionized water. The mixture was allowed to incubate for 30 minutes at
room temperature. A standard sodium nitrated solution (Invitrogen Corp., Carlsbad, CA)
was prepared ranging from 1 to 100 µM by diluting the sodium nitrate solution with
deionized water to produce a standard curve. Using a Spectra Max M2 (Molecular
Devices, Sunnyvale, CA) the absorbance was measured at 548nm.
DNA Relaxation. Nuclear extracts with topoisomerase I activity were prepared using the
procedure from (Walker & Saravia, 2009). 1x109 sensitive and resistant amastigotes were
centrifuged at 1,500 g for 5 minutes. Then resuspended in 800 µl of Hepes buffer (HepesKOH, 10 mM, pH 7.9, 1.5 mM KCL, 0.5 mM dithiothreitol (DTT), 0.2 mM PMSF, 0.2 x
PIC) on ice for 10 minutes followed by sonication twice for 30 seconds with a 60 second
rest. The samples are then centrifuged at 16,000 g for 5 minutes and then the supernatant
is removed and the pellet is resuspended in 100 µl of topoisomerase I extraction buffer
(Tris-HCL, 12.5 mM, pH 7.5, 10 mM MgCL2, 50 mM KCL, 30 µg/ml BSA, 5 %
glycerol, 0.5 mM DTT, 0.2 mM PMSF, 0.2 x PIC) and lysed on ice with a 25-gauge
needle syringe. The lysate was then centrifuged by 16,000 g for 30 minutes and the
supernatant was mixed with 33 µl of topoisomerase I extraction buffer (with 18 % PEG,
and 18 % glycerol) and incubated on ice for 60 minutes with periodic agitation. Another
30 minute 16,000 g centrifugation step was performed and the supernatant was used
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immediately for DNA relaxation determination after protein quantity was assessed using
the Bradford assay method.
DNA relaxation of extracted topoisomerase I enzyme was determined using a
florescent-based DNA topoisomerase I assay kit from ProFoldin (Westborough, MA). In
a 96 well plate each well contained a 40 µl reaction including: 28 µl of H20, 4 µl of 10 x
buffer T1, 4 µl of 10 x supercoiled DNA, 4 µl of 10 x enzyme and incubated at room
temperature for 60 minutes. Reaction concentrations included 16 mM Tris–HCL, pH 8, 6
mM MgCL2, 25 µg/ml supercoiled plasmid DNA and 40 nM topoisomerase I. Negative
control included four additional µl of H20 in lieu of enzyme and the positive control had
E. coli topoisomerase I. fifty µl of 1x H19 dye (100 x H19 dye with 10 mM Tris-HCl, 10
mM NaCl, pH 7.0) was added to each reaction mixture and incubated at room temp for 5
minutes. Fluorescence intensity was measured at 538 nm using the excitation wavelength
at 485 nm every 5 minutes for 25 minutes.
Fluorescent miltefosine. Miltefosine was tagged with a phenyl all (E) polyene
fluorescent fluorophore. It was synthesized using the following conditions:
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Two µM of fluorescent miltefosine was incubated with 1 x 107 Milt-S and Milt-R
parasites were seeded in 8 separate. Each hour for a total of 8 hours, a tube was
centrifuged at 3000 rpm for 5 minutes and washed twice with PBS. The cell suspension
was transferred to the funnel of an E-Z Cytospin (Thermo Scientific, Rochester, NY) and
centrifuged. Cells were attached to an alcohol-washed microscope slide by spinning at
800 RPM for 5 minutes and the slides air-dried and fixed in methanol. The slides were
then imaged with a DAPI filter using a Zeiss observer Z1 (Zeiss, Oberkochen, Germany).
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Results
Establishment of Stable Miltefosine Resistance. MHOM/SD/75/1246/130 L. donovani
axenic amastigotes were exposed to miltefosine in a stepwise discontinuous process for
12 weeks to establish a resistant line with an IC50 50 fold higher than its sensitive parent.
The shift in IC50 value over time is illustrated in figures 3.1 and 3.2. After 8 weeks off
drug pressure a stable phenotype was observed. Clones were selected for characterization
from the sensitive Milt-S parent and resistant Milt-R lines. After each week of pressure a
split was separated and kept off pressure for 4 weeks to assess stability of the resistance
phenotype. Week 1 through 5 of miltefosine pressure all reverted to a miltefosine
sensitive phenotype (figure 3.1) Week 6 with 6 µg/ml of miltefosine pressure with an
IC50 to miltefosine of 30 µM remained stable along with all subsequent weeks of pressure
ending on the 12th week (figure 3.1).
Infectivity in Vitro and in Vivo. Infectivity of Milt-S and Milt-R was tested in vitro in
the infected macrophage model resulting in large numbers of amastigotes visible in the
cytoplasm of J774 and BALB/c mouse peritoneal macrophages (figure 3.3). Infectivity of
macrophages was counted over 24, 48, 72, and 96 hours. Counting all the amastigotes for
every 500 macrophages the result was an increase in the number of amastigotes over time
(figures 3.4 and 3.5) Using the infected macrophage drug assay it was observed that MiltR maintained had a more dramatic miltefosine resistance phenotype with an IC50 value 62
fold above Milt-S (table 3.5).
In vivo Milt-S and Milt-R cell lines were tested for infectivity and miltefosine
susceptibility in Syrian hamsters. Both Milt-S and Milt-R amastigotes produced viable
infections by LDUs of the liver, spleen and, bone marrow (figure 3.6). Milt-S parasite
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burden was reduced 85 and 95 % in hamsters treated for 5 days with 30 and 50 mg/kg of
miltefosine, respectively. In comparison, for Milt-R infected hamsters, parasite burden
was reduced by only 40 % at the maximal tolerated dose (50 mg/kg miltefosine) and was
not affected at all by 30 mg/kg miltefosine (Figure 3.7). A similar drug response was
found in the spleen (figure 3.8). Milt-R parasites were recovered from the infected liver
exposed to 50 mg/kg of miltefosine and cultured in vitro demonstrating the viability of
amastigotes seen in figure 3.6. These resistant parasites removed from the hamster is
designated Milt-HR.
Growth and Stress. Milt-S, Milt-R, and Milt-HR demonstrated a similar growth rate
with a doubling time around 28 hours at 37 °C. However, Milt-S and Milt-R had a similar
reduced doubling time at 38 °C of 61.8±2.1 and 54.2±1.9 respectively, while Milt-HR
had a greater doubling time of 31.7±1.8 (figure 3.9). Under 30 minutes of 0.001% H202
stress the growth rate was reduced similarly between Milt-S, Milt-R, and Milt-HR (figure
3.9). Growth of all lines were reduced when exposed to 40 °C or H202 higher than
0.001%.
Greiss reagent is used to measure nitrate as an estimate of nitrous oxide (NO)
production. Milt-S and Milt-R infected J774 macrophages were exposed to 3 µM of
miltefosine or just PBS for 24 hours and NO production was estimated by Greiss (figure
3.10). There was no difference between Milt-S and Milt-R infected macrophages’ NO
production with or without miltefosine. However, miltefosine caused a similar spike in
NO production for both Milt-S and Milt-R infected macrophages. It is know that
miltefosine causes an increased of NO production in leishmania-infected macrophages,
but NO production of macrophages infected with miltefosine resistant leishmania has not
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been reported (Ponte, Alves, Sampaio, Urdapilleta, Kuckelhaus, Muiz-Junqueria, &
Kuckelhaus, 2012).
Reaction to Drugs. Several standard antileishmanial drugs were screened using the
sensitive and resistant parasites to determine if any cross-resistance were present (table
3.5). No cross-resistance was discovered in Milt-S except with the miltefosine analogs:
edelfosine and ilmofosine. Resistance to miltefosine and analogs was observed in both
the axenic amastigote and infected macrophage assays. Interestingly, Milt-R was found to
be significantly more sensitive to topoisomerase I drugs, Hoechst-3342, topotecan, and
camptothecin (table 3.6) in both the axenic and infected macrophage models. Also, MiltR was found to be more sensitive to the topoisomerase II drug daunomycin. No other
differences were found with standard antileishmanial drugs, and with the drugs
atovaquone and myxothiazol targeting cytochrome B (table 3.7), methylene blue, SHAM,
and antimycin A targeting cytochrome C (table 3.7), theophylline and propyl gallate
targeting pyridoxal kinase (table 3.8).
DNA Relaxation. Measuring DNA relaxation of supercoiled DNA in the presence of
topoisomerase I, we found that Milt-S topoisomerase I relaxed 20 % less supercoiled
DNA than Milt-R after 20 minutes (figure 3.11). The occurrence of a change in DNA
relaxation rate occurred at week 4 of drug pressure (figure 3.12) and remained after
discontinuation of drug pressure.
Sequencing. Several genes were sequenced based on sequences available for Leishmania
infantum on TriTrypDB. The genes selected were sequenced in both Milt-S and Milt-R.
LinJ.12.1590 (LdMT, Figure A-1) and LinJ.32.1040 (Ros3, Figure A-6) were selected
because LdMT and Ros3 are responsible for inward translocation of miltefosine in
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leishmania (Perez-Victoria, 2003: Perez-Victoria 2005). LinJ.02.0020 (cytochrome B, A2), and LinJ.16.1380 (cytochrome C, A-3) were selected because miltefosine has been
demonstrated to release cytochrome C into the cytoplasm of Leishmania and is thought to
be involved in miltefosine’s mechanism of action (Luque-Ortega, & Rivas, 2007).
LinJ.34.2460 (phospholipid-transporting ATPase-like protein, Figure A-4) codes for the
same class of protein as LdMT, which has not previously been investigated for
involvement in miltefosine resistance. LinJ.07.0060 (α-adaptin, Figure A-5) and
Linj.30.1310 (pyridoxal kinase, Figure A-7) were previously found to have mutations in
L. major and L. donovani lines resistant to miltefosine (Coelho et al., 2012), LinJ.28.2450
(DNA topoisomerase ii, Figure A-8), Linj.34.3220 (DNA topoisomerase IB, large
subunit, Figure A-9), and LinJ.04.0070 (DNA topoisomerase IB, small subunit, A-10)
were sequenced because of Milt-R was found to be more sensitive to topoisomerase
inhibitors than Milt-S (table 3.6). From these gene sequences several novel mutations
were found in LinJ.12.1590 (LdMT, figure 3.13), LinJ.07.0060 (α-adaptin, figure 3.14),
Linj.30.1310 (pyridoxal kinase, figure 3.15) that confer amino acid changes between
Milt-S and Milt-R. The mutations that resulted in nonsynominous amino acid changes are
presented in table 3.9.
Pyrosequencing. Pyrosequencing was used to rapidly detect selected SNPs in samples
generated through stepwise drug pressure (table 3.4). Due to the high cost of
pyrosequencing we selected only 6 SNPs to track over the course of miltefosine
resistance development (table 3.4). Three of the SNPs α-adaptin G2728C (A910T),
pyridoxal kinase A239C (S47R), and A43C (Q11H), were only detectable in the clones.
The pyridoxal kinase SNPs were selected because they located in the active site. All of
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the LdMT mutations were selected because mutations in LdMT have been demonstrated
to confer resistance (Perez-Victoria. 2003). LdMT G2751C (K919N) became detectable
at week 6 and LdMT G2411A (D897N) became detectable at week 7 and remained
detectable through subsequent weeks. LdMT T2845G (V951F) became detectable at 8,
which marks the final large IC50 value change (figure 3.16).
qRT-PCR. Relative gene expression was measured for several genes of interest with
Milt-S and Milt-R clones (figure 3.17). Of the genes measured the only differences in
expression were found in topoisomerase II, topoisomerase IB large subunit, and
topoisomerase IB small subunit, with fold change of 3.2, 2.88, and 2.5 respectively. A
similar trend was found in relative expression levels when exposed to miltefosine for 24
hours prior to harvest (figure 3.18) Interestingly, when exposed to miltefosine, Milt-S had
a higher relative expression of pyridoxal kinase than Milt-R.
Mutated Pyridoxal Kinase Transfection. The mutated pyridoxal kinase was
synthetically inserted in a pIDTSmart Amp plasmid and transfected into the wild type
Milt-S (figure 3.19) Successful transfection of the plasmid was confirmed by PCR of
pIDTSmart Amp. Transfection did not significantly alter the Milt-S IC50 value or alter the
IC50 values of pyridoxal kinase drugs.
Protein Homology Modeling. Amino acid sequences of Milt-S and Milt-R pyridoxal
kinase submitted to Swiss Model used human pyridoxal kinase’s X-ray crystallography to
mathematically model the protein tertiary structure (figure 3.20) Milt-S pyridoxal kinase
has a 30 % identity to human pyridoxal kinase with a QMEAN Z-Score of -3.37. Milt-R
has a 29 % identity to human pyridoxal kinase with a QMEAN Z-Score of -4.16. The
Milt-R pyridoxal kinase model has structural difference in loop II, which guards the
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active site with no changes in the ATP binding site. An accurate homology model could
not be generated for LdMT and α-adaptin because no suitable template structures could
be found by Swiss Model.
Fluorescent Miltefosine. The fluorescent miltefosine molecule was first evaluated for
activity on L. donovani. In the axenic amastigote model fluorescent miltefosine had an
IC50 of 7.6±0.5 (Milt-S) and 150±4 µM (Milt-R) compared to 3.2±0.3 µM (Milt-S) and
147±3 µM (Milt-R) for miltefosine. In the infected macrophage model fluorescent
miltefosine had an IC50 of 3.3±0.3 (Milt-S) and 1.4±0.2 µM (Milt-R) compared to 92±0.9
µM (Milt-S) and 90±0.5 µM (Milt-R) for miltefosine. Subsequently, two µM of
fluorescent miltefosine were added to Milt-S and Milt-R and observed over time. Time
point were collected after washing with PBS, fluorescent miltefosine became visible in
the cytoplasm of Milt-S at hours 5-8 but never in the Milt-R samples (figure 3.21).
Discussion
The induction of miltefosine resistance has been shown to be a rapid process in
vitro using Leishmania promastigotes (Perez-Victoria et al., 2001). Here we show for the
first time that in only 12 weeks axenic amastigotes of Leishmania donovani can develop a
strong, stable drug resistant phenotype that is maintained both in vitro and in vivo.
Interestingly, we found that Milt-R is more sensitive to drugs that target topoisomerase I
and II. L. tropica resistant to daunomycin, a topoisomerase II inhibitor was exposed to
miltefosine to induced miltefosine resistance. This line resistant to both miltefosine and
daunomycin showed increased expression of MDR1 (Perez-Victoria et al., 2001). Our
cell line, which only has resistance to miltefosine and its analogs, do not show an
increase in expression of MDR1.
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Involvement of topoisomerase I in miltefosine drug resistance has not been
previously reported. Measuring DNA relaxation by topoisomerase I, we found that MiltR has a 20 % increase in DNA relaxation after 20 minutes compared to Milt-S (figure
3.11). Measuring DNA relaxation over the course of inducing drug resistance (figure
3.12) we found by week four the difference in DNA relaxation between Milt-S and MiltR emerges. Looking at the sequences of topoisomerase I and II no mutations were found
(figures A-8, A-9, & A-10). However, a relative increase in topoisomerase I and II
expression was observed in Milt-R (figures 3.17 & 3.18). It has been shown that there is
an increase in topoisomerase activity in the presence of oxidative stress (Li, Chen, Yu,
Mao, Wang, & Liu, 1999). The increase in topoisomerase expression and DNA
relaxation could be evidence of increased expression of another gene involved in
miltefosine resistance that could be found with a microarray. Alternatively, it could be a
reaction of oxidative stress induced by miltefosine.
Investigating oxidative stress and it interaction with miltefosine resistance, Milt-S
and Milt-R were exposed to H202 and their growth was measured. No appreciable
difference was measured in their growth (figure 3.9). Also there was no difference in IC50
values when exposed to drugs targeting cytochrome B and C (table 3.7). Further
investigation found no mutations in cytochrome B and C (A-2 and A-3) An increase in
NO production was detected in the presence of miltefosine as similarly demonstrated
(Ponte et al., 2012). However, Milt-S and Milt-R had the same level NO production when
exposed to miltefosine (figure 3.10). Therefore, differential reaction to oxidative stress is
not a mechanism of miltefosine resistance.
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Coelho et al., sequenced the genome of a miltefosine resistant L. major cell line
and found mutations in the miltefosine transporter, pyridoxal kinase, α-adaptin and genes
with no orthologs in L. infantum (2012). They also sequenced those genes in a
miltefosine resistant L. infantum line and found two mutations in the miltefosine
transporter and two mutations in the α-adaptin genes (Coelho et al. 2012) We sequenced,
LdMT, Ros3, pyridoxal kinase and α-adaptin and LinJ.34.2460 a phospholipidtransporting ATPase-like protein similar to LdMT in our L. donovani line. Several
mutations were found in LdMT, pyridoxal kinase, and α-adaptin which resulted in
nonsynomonus mutations (table 3.6). The mutations we found are different than the
mutations found in the literature. LdMT and Ros3 have been sequenced by in several
miltefosine selected lines which have resulted in mutations in both trans membrane and
non trans membrane regions. Using pyrosequencing, the three LdMT mutations, two
pyridoxal kinase and one α-adaptin SNPs were followed over the course of increasing
miltefosine drug pressure (figure 3.16). Interesting each mutation in the LdMT gene is
associated with an IC50 change K919N, D897N, V951F occurred at week 6, 7, and 8,
respectively. The pyridoxal kinase and α-adaptin mutations may be compensating, as
they did not appear until after Milt-R had reached its highest level of milt resistance.
Pyridoxal kinase is integral to the vitamin B6 pathway (Scott & Phillips, 1997),
and catalyzes the ATP-dependent phosphorylation of pyridoxal, pyridoxine, and
pyridoxamine into pyridoxal-5’phosphate, the active form of vitamin B6 (Scott &
Phillips, 1997). Our homology model of pyridoxal kinase shows mutations are in loop II
of the protein, but the ATP binding site is unaffected (figure 3.20) Despite these
mutations we found no IC50 changes in response of pyridoxal kinase drugs tested (table
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3.8). In the presence of 3 µM of miltefosine, Milt-R had a relatively lower expression of
pyridoxal kinase (figure 3.18).
Theoretically, Milt-S has a higher expression of pyridoxal kinase because it has
to deal with the stress of miltefosine while 3 µM of miltefosine would not cause Milt-R
stress because it will not be transported into the cell. When the stress of miltefosine is
removed, Milt-S and Milt-R have the same relative expression of pyridoxal kinase (figure
3.17). Transfection of the mutated pyridoxal kinase into Milt-S did not yield any
significant changes in IC50 values (table 3.8). However, it was an episomal transfection
and the wild type pyridoxal kinase was not knocked out. The success rate of a stable
transfection in leishmania is up to 5 % (Beverley, 2002) Additionally, the pyridoxal gene
is essential so knocking it out to properly to assess the mutated pyridoxal kinase is not
possible.
α-adaptin is another gene that had several mutations late in the drug selection
process. Adaptins are proteins that mediate the formation of vesicles; α-adaptin is a
marker for endocytosis (Dornan, Jackson, & Gay, 1997). Mutations in α-adaptin have
only been shown to occur in parasites with miltefosine resistance far beyond what is
clinically relevant (Coelho et al., 2012) It has also been demonstrated that in culture large
quantities of miltefosine will bind to albumin and enter cells through endocytosis (Small,
Strum, & Daniel, 1997). Speculatively, selective pressure against the miltefosine and
albumin complex results in mutations in the α-adaptin gene. It is likely that mutations in
α-adaptin are a result of these high pressures that are beyond clinical relevance.
Our Milt-R cell line is more resistant than any previously reported lab selected
lines of leishmania resistant to miltefosine found in the literature confirmed by the
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reliable MTS assay. Therefore, we wanted to see where miltefosine would localize in the
parasites and see if would efflux. Fluorescently labeled miltefosine was used to see the
localization of miltefosine. The florescent miltefosine maintained activity in both the
axenic amastigote and infected macrophage models. And Miltefosine is visible in the
cytoplasm of Milt-S (figure 3.21) In the case of Milt-R the fluorescent drug is not visible
in the parasite. If an efflux pumps were effluxing miltefosine out of the cell we would
have seen fluorescent miltefosine in the cytoplasm of Milt-R followed by clearing over
time. Therefore, it is likely that mutations in LdMT rendered the transporter nonfunctional so the drug was unable to enter the parasite at the 2 µM concentrations tested.
Conclusion
This is the first study of miltefosine resistance using axenic amastigotes.
Miltefosine resistance is complex and multifactorial. However, mutations in the
miltefosine transporter (LdMT) gene are the primary explanation for the rapid and
dramatic shifts in miltefosine drug resistance in both promastigote and now axenic
amastigote cell lines. Interestingly, in the miltefosine resistant leishmania lines reported
in the literature, all had mutations in the miltefosine transporter but in different locations,
including a miltefosine resistant parasite found in a patient (Cojean et al., 2012). This is
important to know for monitoring miltefosine drug resistance in the field. The diversity of
mutations means that monitoring programs will unlikely be able to pyrosequence a large
number of samples with a few select SNPs but rather will need to sequence the entire
3294 base pair miltefosine transporter gene.
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Table 3.1 qRT-PCR Primers
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Table	
  3.2:	
  PCR	
  Primers	
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Table 3.3: Sequencing Primers
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Table 3.4 Pyrosequencing Primers
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Figure 3.1. Stepwise Increase in Miltefosine Drug Pressure
L. donovani axenic amastigote were put under one µg/ml of miltefosine pressure for four
days followed by three days off pressure. Each successive week the drug pressure was
increased by one µg/ml. At week 12 with 12 µg/ml of drug pressure the parasites were
allowed to grow for an additional 8 weeks and they maintained their resistant phenotype	
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Figure 3.2: Shift in IC50 of Miltefosine Resistance
Analysis of miltefosine dose response curves of Milt-S and Milt-R using sigma plot
software. In week one Milt-S and Milt-R had similar dose responses around 3.3 µM.
The shift in IC50 values is evident by week four with 6.5 µM for Milt-R and more
dramatic by week seven with an IC50 of 85 µM. One year off of drug pressure the shift
in dose response between Milt-S and Milt-R is stable with Milt-R’s IC50 at 148 µM.
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Figure 3.3: Infected J774 and Peritoneal Macrophages
In vitro infection of J774 macrophages by Milt-S (A) and Milt-R (B). Milt-S (C) and
Milt-R (B) also successfully infected BALB/c peritoneal macrophages. In all cases
macrophages were incubated with axenic amastigotes for 4 hours prior to washing
with PBS. Infected macrophages were stained with Geimsa for 5 minutes and
imaged at 100x.
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Figure 3.4: Infected J774 Macrophage Model
Parasite burden peer 500 J774 macrophages measured over 96 hours. Both Milt-S and
Milt-R have a steady increase in parasite numbers each successive 24-hour period.
Measurements were taken in triplicate and the error bars denote standard deviation.
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Figure 3.5: Infected Peritoneal Macrophage Model
Parasite burden peer 500 BALB/c peritoneal macrophages measured over 96 hours. Both
Milt-S and Milt-R have a steady increase in parasite of numbers each successive 24-hour
period. Measurements were taken in triplicate and the error bars denote standard deviation.
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Figure 3.6: Infected Liver Tissue
Impression smears of Syrian hamster liver infected by axenic amastigotes. Milt-S and
Milt-R’s controls 50 mg/kg of miltefosine and have LDU’s 89011±242, 9019±278,
4560±58, 52810±163 respectively. Milt-S and Milt-R both produced robust infections in
the hamsters. When hamsters were treated orally with 50 mg/kg of miltefosine Milt-R
has dramatically greater survivor ability than Milt-S. Images are stained with Geimsa for
5 minutes and imaged at 40x.
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Table 3.5 In Vitro IC50 Values of Miltefosine and Standard Antileishmanial Drugs
	
  

In vitro IC50 values for axenic amastigotes exposed to Miltefosine, its analogs and
standard antileishmanial drugs for 72 hours by MTS assay in µM. Measurements were
taken in triplicate.
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Table 3.6 In Vitro IC50 Values of Topoisomerase Inhibitors

In vitro IC50 values for axenic amastigotes exposed to topoisomerase I inhibitors
(topotecan, camptothecin, and Hoechst-33342) and topoisomerase II inhibitor
(Daunomycin) for 72 hours by MTS assay in µM. Measurements were taken in
triplicate.
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Table 3.7 In Vitro IC50 Values of Cytochrome Inhibitors

In vitro IC50 values for axenic amastigotes exposed to cytochrome C inhibitors
(Methylene Blue, SHAM, and Antimycin A) and cytochrome B inhibitors
(Atovaquone and Myxothiazol) for 72 hours by MTS assay in µM. Measurements
were taken in triplicate.
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Table 3.8 In Vitro IC50 Values of Pyridoxal Kinase Inhibitors

In vitro IC50 values for axenic amastigotes exposed to pyridoxal kinase inhibitors
for 72 hours by MTS assay in µM. Measurements were taken in triplicate.
	
  

	
  

94	
  

	
  

*	
  

Figure 3.7: Quantification of Parasites in Hamster Liver
When exposed to 30 and 50 mg/kg of miltefosine in vivo Milt-S has an 85 to 95%
reduction in parasite burden in the liver respectively. Milt-R has a negligible reduction
at 30 mg/kg and 40 % reduction in parasite burden in the liver when exposed to 50
mg/kg of miltefosine in vivo. Results were collected using LDU and real time PCR
methods and error bars denote standard error with four hamsters per group. Student ttest determined statistical significance, *p=0.0001, **p=0.0003, ***p=0.002,
****p=0.002.
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Figure 3.8: Quantification of Parasites in Hamster Spleen
When exposed to 30 and 50 mg/kg of miltefosine in vivo Milt-S has an 80 to 87 %
reduction in parasite burden in the spleen respectively. Milt-R has a negligible
reduction at 30 mg/kg and 40 % reduction in parasite burden in the spleen when
exposed to 50 mg/kg of miltefosine in vivo. Results were collected using LDU and
real time PCR methods and error bars denote standard error with four hamsters per
group. Student t-test determined statistical significance, *p=0.0006, **p=0.0002,
***p=0.0001, ****p=0.0008.	
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Figure 3.9: In Vitro Growth Under Stress of Axenic Amastigotes
Milt-S, R, and HR were seeded in flasks at 1x106 in flasks and growth was measured
every 24 hours over a 72-hour period under various heat and H2O2 stresses. In optimal
conditions at 37 oC they all had similar growth with a doubling time around 28 hours.
Under slight heat stress of 38 oC they all had reduced doubling times. However, MiltHR grew much better under heat stress. All the parasites has a significantly reduced
doubling time when exposed to H2O2 stress. Measurements were taken in triplicate and
error bars denote standard error.
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Figure 3.10: Nitrate Production Measured by Greiss Reagent
Greiss Reagent was used to measure nitrate levels in samples as an estimate of nitrous
oxide (NO) production in J774 macrophages. Pure nitrate samples were serially diluted
and measured to establish a standard curve and J774 exposed to LPS and IF gamma was
designated as 100 % NO production. Milt-S and Milt-R infected macrophages similarly
had around 55 % NO production. When exposed to 3 µM of miltefosine they had a similar
increase in NO production around 80 %. Measurements were taken in triplicate and error
bars denote standard error. Student t-test determined statistical significance, *p=0.007,
**p=0.004, ***p=0.2.
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Figure 3.11: Topoisomerase I DNA Relaxation Over Time
Percentage	
  of	
  DNA	
  relaxation	
  by	
  topoisomerase	
  I	
  over	
  5	
  minute	
  increments	
  for	
  25	
  
minutes.	
  E.	
  coli	
  topoisomerase	
  I	
  on	
  the	
  left	
  was	
  used	
  as	
  a	
  control.	
  Milt-‐R	
  
topoisomerase	
  I	
  extracted	
  relaxed	
  supercoiled	
  DNA	
  at	
  a	
  greater	
  rate	
  than	
  Milt-‐S.	
  
Measurements were taken in triplicate and error bars denote standard error. Student ttest determined statistical significance, *p=0.02.
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Figure 3.12: Topoisomerase I DNA Relaxation Over Stepwise Increasing
Miltefosine Drug pressure After 20 Minutes
Measuring	
  DNA	
  relaxation	
  activity	
  after	
  20	
  minutes	
  of	
  topoisomerase	
  I	
  activity	
  in	
  
samples	
  from	
  figure	
  3.1.	
  Milt-‐R’s	
  topoisomerase	
  I	
  activity	
  increases	
  in	
  the	
  weak	
  
four	
  samples	
  and	
  perpetuates	
  over	
  samples	
  from	
  subsequent	
  weeks.	
  Measurements
were taken in triplicate and error bars denote standard error. Student t-test determined
statistical significance, *p=0.5, **p=0.01, ***p=0.001.
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Figure 3.13: LinJ.13.1590 (LdMT) Sequence Alignment
Alignment of LinJ.13.1590 (LdMT) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.13.1590 is a
3294 base pair sequence coding for a phospholipid-transporting ATPase-like protein.
Red highlights indicate mutations detected.
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Figure 3.14: LinJ.07.0060 (α-adaptin) Sequence Alignment
Alignment of LinJ.07.0060 (α-adaptin) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.07.0060 is a
2886 base pair sequence coding for a α-adaptin-like protein. Red highlights indicate
mutations detected.
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Figure 3.15: LinJ.30.1310 (pyridoxal kinase) Sequence Alignment
Alignment of LinJ.30.1310 (pyridoxal kinase) Nucleotide Sequences in L. infantum
from TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.30.1310 is
a 909 base pair sequence coding for a pyridoxal kinase protein. Red highlights indicate
mutations detected.
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Figure	
  3.16:	
  Pyrosequencing	
  of	
  SNPs	
  
Pyrosequencing of SNPs found in table 3.4 revealed the emergence of mutations in the
LdMT gene early in the drug selection process and are maintained in the subsequent
weeks. The pyridoxal kinase and α-adaptin’s SNPs appear late after the high drug
resistant phenotype is established.
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Figure 3.17: Gene Expression Without Miltefosine Pressure
Relative expression of α-adaptin, LdMT, pyridoxal kinase, MDR1, topoisomerase II,
topoisomerase I large and small subunit by qRT-PCR. Relative expression was
normalized to Milt-S and GAPDH was used as a control. Measurements were taken in
triplicate and error bars denote standard error. Student t-test determined statistical
significance, *p=0.2, **p=0.003, ***p=0.02, ****p=0.02.
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Figure 3.18: Gene Expression After 3 µM Miltefosine Exposure for 24 Hours
Relative expression of α-adaptin, LdMT, pyridoxal kinase, MDR1, topoisomerase II,
topoisomerase I large and small subunit by qRT-PCR under 3µM of Miltefosine
pressure. Relative expression was normalized to Milt-S and GAPDH was used as a
control. Measurements were taken in triplicate and error bars denote standard error.
Student t-test determined statistical significance, *p=0.02, **p=0.004, ***p=0.01,
****p=0.007.
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Table 3.9 Nonsynomonous Amino Acid Changes	
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Milt-R Pyridoxal Kinase

Figure 3.19: Mutated Pyridoxal Kinase Transfection Plasmid
Mutated LinJ.30.1310 from Milt-R was synthetically genetrated and inserted into
pIDTSmart Amp expression plasmid by IDT. Adapted from pIDTSmart-amp-genmap-pdf. Copyright 2013, Integrated DNA Technologies, Inc.
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Figure 3.20: Protein Homology Model
Homology modeling for both Milt-S (left) and Milt-R (right) used human pyridoxal
kinase as the reference structure. Milt-S pyridoxal kinase has a 30% identity to human
pyridoxal kinase with a QMEAN Z-Score of -3.37. Milt-R has a 29% identity to human
pyridoxal kinase with a QMEAN Z-Score of -4.16.
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Figure 3.21: Localization of Fluorescent Miltefosine
Live cell imaging of Milt-S and Milt-R with 2 µ of fluorescent miltefosine. Images
taken every hour with DAPI filter using a Zeiss Observer Z1. Fluroescent miltefosine is
detectable in the cytoplasm of of Milt-S at hours 5-8. No Fluroescent miltefosine was
detected in Milt-R. Hours 1-4 were inconclusive.

	
  

110	
  

List of References
Arnold, K., Bordoli, L., Kopp, J., & Schwede, T. (2006). The SWISS-MODEL
workspace: A web-based environment for protein structure homology modeling.
Bioinformatics, 22(2), 195-201.
Arthur, G., & Bittman, R. (1998). The inhibition of cell signaling pathways by antitumor
ether lipids. Biochimica Et Biophysica Acta, 1390(1), 85-102.
Beverley, S. M. (2003). Protozomics: Trypanosomatid parasite genetics comes of age.
Nature Reviews Genetics, 4(1), 11-19.
Bhandari, V., Kulshrestha, A., Deep, D. K., Stark, O., Prajapati, V. K., Ramesh, V., . . .
Salotra, P. (2012). Drug susceptibility in leishmania isolates following miltefosine
treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
PLoS Neglected Tropical Diseases, 6(5), e1657.
Biyani, N., Mandal, S., Seth, C., Saint, M., Natarajan, K., Ghosh, I., & Madhubala, R.
(2011). Characterization of leishmania donovani aquaporins shows presence of
subcellular aquaporins similar to tonoplast intrinsic proteins of plants. PloS One,
6(9), e24820.
Castanys‐Muñoz, E., Alder‐Baerens, N., Pomorski, T., Gamarro, F., & Castanys, S.
(2007). A novel ATP‐binding cassette transporter from leishmania is involved in
transport of phosphatidylcholine analogues and resistance to alkyl‐phospholipids.
Molecular Microbiology, 64(5), 1141-1153.

	
  

111	
  

Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., . . . Boelaert, M.
(2007). Visceral leishmaniasis: What are the needs for diagnosis, treatment and
control? Nature Reviews Microbiology, 5(11), 873-882.
Coelho, A. C., Boisvert, S., Mukherjee, A., Leprohon, P., Corbeil, J., & Ouellette, M.
(2012). Multiple mutations in heterogeneous miltefosine-resistant leishmania major
population as determined by whole genome sequencing. PLoS Neglected Tropical
Diseases, 6(2), e1512.
Cojean, S., Houzé, S., Haouchine, D., Huteau, F., Lariven, S., Hubert, V., . . . Le Bras, J.
(2012). Leishmania resistance to miltefosine associated with genetic marker.
Emerging Infectious Diseases, 18(4), 704-706.
Dornan, S., Jackson, A. P., & Gay, N. J. (1997). Alpha-adaptin, a marker for endocytosis,
is expressed in complex patterns during drosophila development. Molecular Biology
of the Cell, 8(8), 1391-1403.
Huang, X., & Madan, A. (1999). CAP3: A DNA sequence assembly program. Genome
Research, 9(9), 868-877.
Kiefer, F., Arnold, K., Künzli, M., Bordoli, L., & Schwede, T. (2009). The SWISSMODEL repository and associated resources. Nucleic Acids Research, 37(suppl 1),
D387-D392.

	
  

112	
  

Nicolas, L., Prina, E., Lang, T., & Milon, G. (2002). Real-time PCR for detection and
quantitation of leishmania in mouse tissues. Journal of Clinical Microbiology, 40(5),
1666-1669.
Peitsch, M. C. (1995). Protein modeling by E-mail. Bio Technology, 13, 658-660.
Pérez-Victoria, F. J., Sánchez-Cañete, M. P., Castanys, S., & Gamarro, F. (2006).
Phospholipid translocation and miltefosine potency require both L. donovani
miltefosine transporter and the new protein LdRos3 in leishmania parasites. Journal
of Biological Chemistry, 281(33), 23766-23775.
Pérez-Victoria, F. J., Castanys, S., & Gamarro, F. (2003). Leishmania donovani
resistance to miltefosine involves a defective inward translocation of the drug.
Antimicrobial Agents and Chemotherapy, 47(8), 2397-2403.
Pérez-Victoria, F. J., Gamarro, F., Ouellette, M., & Castanys, S. (2003). Functional
cloning of the miltefosine transporter. Journal of Biological Chemistry, 278(50),
49965-49971.
Pérez-Victoria, F. J., Sánchez-Cañete, M. P., Seifert, K., Croft, S. L., Sundar, S.,
Castanys, S., & Gamarro, F. (2006). Mechanisms of experimental resistance of
Leishmania to miltefosine: Implications for clinical use. Drug Resistance Updates,
9(1), 26-39.

	
  

113	
  

Pérez-Victoria, J. M., Pérez-Victoria, F. J., Parodi-Talice, A., Jiménez, I. A., Ravelo, A.
G., Castanys, S., & Gamarro, F. (2001). Alkyl-lysophospholipid resistance in
multidrug-resistant leishmania tropica and chemosensitization by a novel Pglycoprotein-like transporter modulator. Antimicrobial Agents and Chemotherapy,
45(9), 2468-2474.
Ponte, C. B., Alves, É. A. R., Sampaio, R. N. R., Urdapilleta, A. A. A., Kückelhaus, C.
S., Muniz-Junqueira, M. I., & Kückelhaus, S. A. S. (2012). Miltefosine enhances
phagocytosis but decreases nitric oxide production by peritoneal macrophages of
C57BL/6 mice. International Immunopharmacology, 13(1),114-119.
Rakotomanga, M., Saint-Pierre-Chazalet, M., & Loiseau, P. (2005). Alteration of fatty
acid and sterol metabolism in miltefosine-resistant leishmania donovani
promastigotes and consequences for drug-membrane interactions. Antimicrobial
Agents and Chemotherapy, 49(7), 2677-2686.
Scott, T. C., & Phillips, M. A. (1997). Characterization of trypanosoma brucei pyridoxal
kinase: Purification, gene isolation and expression in escherichia coli. Molecular and
Biochemical Parasitology, 88(1), 1-12.
Seifert, K., Matu, S., Javier Perez-Victoria, F., Castanys, S., Gamarro, F., & Croft, S. L.
(2003). Characterisation of leishmania donovani promastigotes resistant to
hexadecylphosphocholine (miltefosine). International Journal of Antimicrobial
Agents, 22(4), 380-387.

	
  

114	
  

Seifert, K., Pérez-Victoria, F. J., Stettler, M., Sánchez-Cañete, M. P., Castanys, S.,
Gamarro, F., & Croft, S. L. (2007). Inactivation of the miltefosine transporter,
LdMT, causes miltefosine resistance that is conferred to the amastigote stage of
leishmania donovani and persists in vivo. International Journal of Antimicrobial
Agents, 30(3), 229-235.
Sereno, D., Roy, G., Lemesre, J. L., Papadopoulou, B., & Ouellette, M. (2001). DNA
transformation of leishmania infantum axenic amastigotes and their use in drug
screening. Antimicrobial Agents and Chemotherapy, 45(4), 1168-1173.
Singh, G., Chavan, H. D., & Dey, C. S. (2008). Proteomic analysis of miltefosineresistant leishmania reveals the possible involvement of eukaryotic initiation factor
4A (eIF4A). International Journal of Antimicrobial Agents, 31(6), 584-586.
Small, G. W., Strum, J. C., & Daniel, L. W. (1997). Characterization of an HL-60 cell
variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-racglycero-3-phosphocholine. Lipids, 32(7), 715-723.
Srivastava, A., Sweat, J. M., Azizan, A., Vesely, B., & Kyle, D. E. (2012). Real-time pcr
to quantify leishmania donovani in hamsters. Journal of Parasitology, 99(1), 145150.
Stauber, L. A. (1958). Host resistance to the khartoum strain of leishmania donovani.
Rice Institute Pamphlet, 45, 80-96.

	
  

115	
  

Walker, J., & Saravia, N. G. (2004). Inhibition of leishmania donovani promastigote
DNA topoisomerase I and human monocyte DNA topoisomerases I and II by
antimonial drugs and classical antitopoisomerase agents. Journal of Parasitology,
90(5), 1155-1162.

	
  

116	
  

Chapter Four:
In Vitro Fitness of Miltefosine Resistant Leishmania donovani Axenic Amastigote
Cell Line
Abstract
Understanding the fitness of parasites is critical for researchers studying drug
resistance and public health control effort programs in the field in terms of the impact of
dosing, counterfeit drugs, and rapidity of the spread of resistance. Classically, drug
resistance gives the parasite an advantage over its wild type counterparts in the presence
of drug and incurs a fitness cost in the absence of that drug. Leishmania, the causative
agent of the severe disease leishmaniasis has been documented to incur a fitness
advantage in the absence of drug when it is resistant to antimony. This finding has
important implications in the field because it has been shown to spread quicker than the
drug sensitive population confounding the already complex control efforts. Miltefosine is
an important alternative in antimony resistant areas. Unfortunately, miltefosine resistance
is beginning to emerge in the field. Therefore, it is necessary to determine the fitness of
miltefosine resistant parasites. We have found that miltefosine resistant L. donovani
follows the classic model of drug resistant fitness. When exposed to 3 µM or 6 µM of
miltefosine, drug resistant miltefosine (Milt-R) has a fitness advantage in the presence of
drug but has a fitness advantage in the absence of drug pressure. Interestingly, the
miltefosine sensitive parasite (Milt-S) has the fitness advantage in the absence of drug
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pressure and 1 µM of miltefosine, which is, sub IC50 value. This is the first study of
fitness of miltefosine resistant parasites.
Introduction
Leishmania is an important parasite affecting 88 countries (Desjeux, 1996)
Leishmania donovani causes visceral leishmaniasis, a lethal from of leishmania when
untreated (Chappusi, 2007). Leishmania like all pathogens survives and reproduces while
interacting with its environment. The genetic and epigenetic changes that leishmania
develops to respond to environmental stimuli, including drugs, affect its fitness to
survive, reproduce, and transmit in the presence and absence of that stimuli. Most
commonly, when a pathogen acquires drug resistance it incurs a fitness cost in the
absence of that drug (Andersson & Levin, 1999).
Interestingly, both in vitro and in vivo, antimony-resistant leishmania has been
shown to have a fitness advantage over antimony-sensitive leishmania in both the
presence and absence of drug (Ouakad, Vanaerschot, Rijal, Sundar, Speybroeck, Kestens,
Boel, De Doncker, Maes, & Decuypere 2011, Vanaerschot, Doncker, Maes, Duiardin, &
Decuypere, 2010). Antimony has been the first line drug to treat leishmania for over 60
years. Bihar, the region of India with the most visceral leishmania in the world, has 60 %
antimony resistance. The fitness advantage of antimony-resistant leishmania has
important implications for its control in the field (Ait-Oudhia, Gazanion, Vergnes, Oury,
& Sereno, 2011).
Miltefosine is a first line drug in antimony resistant areas when liposomal
amphotericin B cannot be afforded (Singh, Kumar, & Singh, 2012). It is of great concern
that reports of miltefosine resistance are now emerging (Cojean, Houze, Haouchine,
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Huteau, Lariven, Hubert, Michard, Bories, Pratlong, & Bras, 2012, Bhandari,
Kulshrestha, Deep, Stark, Prajapati, Ramesh, Sundar, Schonian, Dujardin, & Salotra,
2012). The fitness of miltefosine resistant leishmania needs to be determined for public
health practitioners in the field to better plan leishmania control efforts and understand
effects drug dosing on the spread of resistance. In this paper we are the first to
demonstrate the fitness of miltefosine resistant leishmania and the first to conduct a
fitness study on axenic amastigotes.
Materials and Methods
Cell Lines. MHOM/SD/75/1246/130 L. donovani axenic amastigotes were cultured in
RPMI 1640 at a pH of 5.5 with 7.5 g/L Hepes (Invitrogen Corp., Carlsbad, CA), 5.86 g/L
MES (Sigma-Aldrich, St Louis, MO), 2 g/L sodium bicarbonate (Fisher Scientific,
Pittsburg, PA), 10 mg/L Hemin (Sigma-Aldrich, St Louis, MO), 100 µM Xanthine
(Sigma-Aldrich, St Louis, MO), 40 mg/L Tween-80 (Sigma-Aldrich, St Louis, MO), 1 %
Penicillin-Streptomycin, 5 g/L Trypton-Peptone (BD Bioscience, Sparks, MD), and 20 %
16 hours heat inactivated Fetal Bovine Serum (FBS). L. donovani was incubated at 37 °C.
All culturing was done using non-vented 25 cm2 tissue culture flasks (Coning, Lowell,
MA)
Cell Viability Assay. The viability of amastigotes was determined by the Cell Titer 96
Aqueous Assay (Promega, Madison, WI) that employs a tetrazolium compound [3-(4,5dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium;
MTS] and electron-coupling reagent, phenazine methosulphate (PMS). Test compounds
are serially diluted in 100 µl of PBS in 96 well plates using a Biomeck 3000 (Beckman
Coulter, Miami, FL). Ten µl of each well was transferred to another 96 well plate and
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then receives 90 µl of parasites in media. The parasites are in a concentration to have
66,000 parasites per well. After 12 hours 20 µl of MTS solution is added to each well in
the 96 well plates. The plates were then incubated at and 37 °C for four hours to achieve
optimal color development. After 4 h of incubation, the OD values were determined at
490 nm using a Spectra Max M2 (Molecular Devices, Sunnyvale, CA). The results were
presented as the percentage of survivors (OD value with test compound divided by that of
untreated control). Curve fitting using non-linear regression was done using table curve
to obtain IC50 values.
Cell Growth. 1 x 106 amastigotes per ml were seeded in 25 cm2 tissue culture flasks and
every 24 hours for 4 days using a hemocytometer (Fisher Scientific, Pittsburg, PA) was
used to calculate the culture density. After exposure to drug pressure, aliquots with 1x106
parasites per ml for 5 mls from each test culture were separated and measured every 24
hours for four days to measure growth. The average of triplicate time points were used to
calculate the growth rate is excel using exponential regression formula Y=be*g*x. The
doubling time was calculated by n=ln(2)/g, with g being the growth rate.
DNA Extraction. DNA extraction was performed using the QIAamp DNA Mini kit
(Qiagen, USA). Using this protocol 80 µl of 2x107 parasites from culture were
centrifuged and resuspended in 80 µl of PBS and were added to 100 µl of tissue lysis
buffer and 20 µl of proteinase K and incubated at 56 °C for 2 hours. Then samples were
loaded into a QIAcube (Qiagen, USA) for DNA extraction. After extraction DNA
concentration was determined in ng/µl using a NanoDrop 1000 spectrophotometer
(Thermo Scientific, Rochester, NY).

	
  

120	
  

PCR. Polymerase Chain Reaction was performed using 50 µl samples with 31.5 µl
DNase free water, 10 µl 5x HF buffer, 1 µl 10 µM DNTPs, 2.5 µl of 10 µM primer A, 2.5
µl of 10 µM primer B, 0.5 µl Phusion Taq polymerase, and 2 µl template DNA. A hot
start PCR was run using a thermo cycler with the following cycles: one cycle 98 °C-30
seconds, 32 cycles 98 °C-10 seconds, 73 °C -30 seconds, 72 °C-112 seconds, and one
cycle at 72 °C-7 minutes, followed by a final hold at 4 °C. PCR products were tested for
band size using a 1 % agarose gel with a 1kb plus ladder (Invitrogen Corp., Carlsbad,
CA). Primers from IDT (Coralville, IA) were used for the Leishmania donovani
miltefosine transporter gene LinJ.13.1590, forward primer 5’CCTGACGATCACACGGACACAC-3’ and reverse primer 5’GGCTTGGTATGTGGCTGCACTC-3’.
Pyrosequencing. Pyrosequencing primers were designed using Biotope Pyro sequencing
Assay Design software (Charlottesville, VA) to amplify the SNP-containing gene. A
LinJ.13.1590 SNP of G2411A resulted in a non-synonymous mutation at location
D897N. Primers used were, forward 5’-AGTCAACCGGTAAGACAGCG-3’, reverse 5’GCACCTTCCAGCCCAATA-3’, and sequencing primer, 5’-AGCGCTGGCCATCGG3’. Primer 5’ biotin label was added to the PCR primer running in the opposite direction
of the sequencing primer. Sequencing primer (0.6 µM) diluted in annealing buffer
(Biotope, Charlottesville, VA) and 40 µl of mixture was aliquoted in a 96-well PSQ plate.
Binding reaction mixture consisted of 4 µl of Streptavidin coated Sepharose beads (GE
Healthcare) and 51 µl of binding buffer. In each well of a 96 well plate 55 µl of binding
mixture was added to 25 µl of PCR product and mixed at 14,000 rpm for 10 minutes.
Using the Vacuum Prep Workstation (Biotope, Charlottesville, VA) the Sepharose-bound
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PCR products were captured with the Vacuum Prep Tool immediately after being mixed
and washed as follows: 70 % ethanol for 10 seconds, denaturing buffer (0.2 M NaOH)
for 10 seconds, and washing buffer (10 mM Tris-acetate, pH 7.6) for 15 seconds. The
vacuum was released and the Sepharose-bound PCR products were released into the PSQ
plate containing sequencing primer. The plate was incubated at 80 °C for 2 minutes and
allowed to cool to room temperature. Plates were read using a PyroMark ID (Biotope,
Charlottesville, VA) in AQ mode using PyroMarkGold Q96 reagent kit (Qiagen, USA).
Assay was completed three times for each DNA template and the average percentage of
wild-type allele was plotted over time.
Fitness Study Protocol
Eighteen non-vented 25 cm2 tissue culture flasks (Coning, Lowell, MA) were
seeded with either 2x107 parasites of Milt-S, Milt-R, or a 50:50 mix of Milt-S and Milt-R
totaling 2x107 parasites. From these groups we had a control, a DMSO control, 1, 3, 5µM miltefosine and 1 µM amphotericin B respectively. Flasks were put under pressure
for four days followed one day off pressure and growth was measured everyday. When
taken off pressure DNA was extracted and MTS assay plate was set up. Also, a 2x107
aliquot was taken and put into a fresh flask for continuation of the study. A total of 18
cycles of pressure were performed. The ratio of sensitive and resistant parasites in mixed
culture was determined using pyrosequencing of a single nucleotide polymorphism
(SNP), D897N previously found in the a Leishmania donovani miltefosine transporter
gene linj.13.1590 (Vesely, Chapter 3)
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Results
Growth. The measurement of growth with and without pressure is an important
determinate of fitness. The doubling times of the Milt-S and Milt-R parasites were
measured without drug pressure to determine if they had similar growth rates. The
doubling time of Milt-S and Milt-R are 27.1±1.2 and 29.3±1.5 hours in the absence of
drug, respectively. Growth was measured to determine doubling time at 1, 3, 6 µM
miltefosine and 1 µM amphotericin B pressure. In the presence of 3 µM miltefosine drug
pressure, the growth of Milt-R was unchanged, but the growth of Milt-S was greatly
affected due to parasite killing. The doubling time for Milt-S exposed to 3 µM
miltefosine was 42.2±2.1 hours (figure 4.1). The doubling time of the 50:50 mixed
culture exposed to 1 µM of miltefosine had a doubling time close to Milt-R in the first
cycle but by the 6 cycle the doubling time increased and was equal to Milt-S by the end
the 18th cycle. When exposed to 3 µM of miltefosine the 50:50 mixed culture has a
doubling time equal to Milt-R throughout the 18 cycles followed. When exposed to 6 µM
of miltefosine the 50:50 mixtures has the same trend as 3 µM of miltefosine exposure.
However, at 6 µM, Milt-S’s doubling time decreases by cycle 9 meaning it became
resistant.
Phenotype. The IC50 values were measured using the MTS assay after each drug pressure
cycle and plotted in figure 4.2. The IC50 values of these Milt-S and Milt-R clones not
exposed to drug pressure remains unchanged throughout the 18 cycles tested with 3.5±0.4
µM and 148±2.2 µM respectively. The Milt-S clone exposed to 6 µM of miltefosine IC50
value rose to 9 µM at the 10th cycle, continued to rise to 40 µM by the 18th cycle (figure
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4.2). It is interesting that such a high increase in resistance was achieved using a constant
drug pressure concentration.
Between the cycles of 0 and 8 the IC50 values of Milt-S and Milt-R remained
unchanged in the presence of drug pressure. At cycle 0 the 50:50 mixed culture has the
IC50 value 6.25± 0.7 µM. Using the harmonic mean (H(a,b)=2/(1/a)+(1/b)) the IC50
values of Milt-S and Milt-R mixed culture are 5.88, which is in the range of the
experimentally derived value. In both the 3 and 6 µM 50:50 mixtures the IC50 steadily
increased until the 5 cycle where the IC50 values were comparable to Milt-R.
Genotype. The wild type SNP was detected by pyrosequencing in all the Milt-S cultures
for the 18 cycles in triplicate. Likewise the resistant SNP was detected by pyrosequencing
in all the Milt-R cultures for the 18 cycles in triplicate (figure 4.3). On day one all the
50:50 mix cultures showed a 50:50 ratio of the wild type and resistant SNP. By the end of
the first cycle the mixed cultures, negative control, DMSO control, amphotericin B drug
control and 1 µM miltefosine had around a 10 % increase in the wild type SNP. In all of
these groups the wild type SNP became more prevalent until the 8th cycle when the
culture was dominated by the wild type SNP. In the case of the mixed cultures under 3
and 6 µM miltefosine pressure the prevalence of the resistance SNP was found to be more
pronounced after the first cycle followed by dominance by the 4th cycle (figure 4.3).
Discussion
Fitness of a drug-resistant versus drug sensitive pathogen is a complex and
multifactorial concept dealing with host and environmental interactions and the
pathogens ability to survive, reproduce, and transmit (Borrell & Gagneux, 2009). For the
purpose of this study we simply define increased fitness as the ability of one clone to
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overtake another in a culture flask over time. We selected a single SNP as a means to
identify the sensitive and resistant clones in mixed cultures. This SNP is a good marker
because it remained unchanged in the controls. Even with Milt-S exposed to 6 µM that
developed a resistant phenotype, the wild type SNP was still present.
Using the standard 72 hour MTS assay resulted in skewed IC50 values in the MiltR range. Using a modified 12 hour MTS assay resulted in IC50 values in the range of the
calculated range of the harmonic mean. The phenotypic IC50 data showed increasing IC50
values of the mixed cultures when exposed to 3 and 6 µM miltefosine, It is clear by the
5th cycle that Milt-R has dominated the culture. In the absence of miltefosine drug
pressure or 1 µM miltefosine which is one third of its IC50 the mixed cultures IC50
approaches the value of Milt-S, which occurs by the 8th cycle.
By the 4th cycle of 3 µM and 6 µM miltefosine drug pressure we observed a
complete shift to the resistant genotype in the mixed populations. Three µM of
miltefosine is the IC50 value for the wild type parasite. The mixed population under 1 µM
miltefosine pressure did not shift in favor of the resistant phenotype. It took 8 cycles for
Milt-S to over grow mixed cultures in the absence of drug pressure or under amphotericin
B drug pressure.
The fitness of miltefosine resistant parasites with and with out drug pressure is
evidenced by the 8th cycle before the IC50 value of 6 µM of miltefosine drug pressure
induced a resistant phenotype. We found the doubling time of Milt-S and Milt-R are both
around 28 hours without drug pressure eliminating a confounding variable in measuring
fitness in mixed populations. Under 3 and 6 µM of miltefosine pressure the Milt-R clone
has a distinct growth so it was able to become the dominant population in the mixed
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cultures by cycle 4. The fitness cost of miltefosine resistance in the absence of
miltefosine is not as dramatic. It takes twice a long for the fitness advantage in the
absence of drug pressure to manifest for Milt-S as the fitness advantage for Milt-R in the
presence of 3 and 6 µM of miltefosine.
The D897N mutation in the miltefosine transporter is a mutation in the trans
membrane region. This structutal change may be responsible for the failure of miltefosine
to enter Milt-R at the concentrations tested. The ability to prevent miltefosine from
entering Milt-R to affect its growth and survival gives it a clear fitness advantage over its
sensitive parent. The absence of the D897N SNP is detrimental in the presence of
miltefosine at Milt-S IC50 or higher. However, Milt-S parasites have the fitness advantage
without drug pressure or with low levels of miltefosine.
It is difficult to extrapolate what would occur in vivo, but this data gives us the
implication that an optimal dose of miltefosine followed by discontimuation of the
correct regimine would lead to rapid selection of resistance in the parasite followed by
the sensitive parasite being more fit in the same host under suboptimal or no miltefosine
drug pressure. Based on the in vitro data baring some unforeseen factors in vivo, it is
unlikely that miltefosine will spread as efficiently as antimony resistance has done. It is
also unknow if miltefosine resistant leishmania can be transmitted the sandfly vector. The
mutations and expression changes that have occurred to survive miltefosine may be
disadvantageous to survival in the sandfly or not be selected during the sexual state. It is
possible that Milt-R could be expressing some virulence factor that would give it the a
fitness advantage over Milt-R with or without miltefosine drug pressure once selected.
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The next step would be to repeat this study using the hamster model. Study of cell
signaling and virulence factors may elucidate the mechanism(s) of Milt-R disadvantage
in the absence of drug compared to Milt-S in vivo. However, this work does show
conclusively in vitro that miltefosine resistance in the L. donovani line follows the classic
model of fitness in contrast to what has been shown for antimony resistant leishmania.
Milt-R has a fitness advantage in the presence of 3 and 6 µM of miltefosine drug pressure
and a fitness cost in the absence of drug pressure.
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Figure 4.1: Growth Over Time Under Miltefosine Pressure
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  cultures	
  measured	
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  each	
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  cycle.	
  Measurements were taken in triplicate and error bars denote
standard error.
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Figure 4.2: Phenotype Over Time
IC50 values of Milt-S, Milt-R, and 50:50 mix after each pressure cycle. IC50 values were
determined using a modified 12 hour MTS assay and analyzed using sigma plot
software. Milt-S (black circle), Milt-R (red circle), and 50:50 mix (green triangle)
Measurements were taken in triplicate and error bars denote standard error.
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Figure 4.3: Genotype Over Time
Tracking of LdMT D897N SNP Milt-S (black circle), Milt-R(red circle), and 50:50
mixed (green triangle) cultures measured after each drug pressure cycle.
Measurements were taken in triplicate and error bars denote standard error.
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Chapter Five:
Summary
Introduction
L. donovani the causative agent of visceral leishmaniasis is predominantly found
in the impoverished Bihar region of India. Unfortunately, the relatively inexpensive
antimony drugs are becoming ineffectual due to widespread drug resistance. In its place
more expensive and for some unaffordable drugs are being used such as amphotericin B
and miltefosine. Miltefosine has the advantage of being the only oral antileishmanial drug
on the market.
Leishmania is a difficult organism to develop drugs against. And development of
oral drugs with low toxicity profiles is even more difficult. With complex biology and
scarcity of large funding sources for leishmania drug development, the drugs on the
market need to be understood and monitored. In the case of miltefosine its mechanism of
action and mechanism(s) of drug resistance are poorly understood. Miltefosine’s
mechanism of action is mainly associated with apoptosis and disturbance of lipiddependent cell signaling pathways (Dorlo, Balasegaram, Beijnen, & de Vries, 2012).
Drug combinations and direct observation therapy might be needed to delay the onset of
widespread resistance.
Miltefosine Resistance in the Literature
The first cell line studied was a multi drug resistant L. tropica line resistant to
daunomycin and miltefosine, which showed, increased expression in the MDR1 gene
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(Perez-Victoria, Perez-Victoria, Parodi-Talice, Jimenez, Ravelo, Castanys, & Gamarco,
2001). This codes for a P-glycoprotein ABC transporter that effluxes the drug (PerezVictoria et al., 2001). The mechanism has not been shown to be present in future lines
that are resistant to miltefosine alone. The next line developed was an L. donovani line
cultured with up to 40 µM of miltefosine and has an IC50 around 75 µM (Seifert, Matu,
Perez-Victoria, Castanys, Gamarro, & Croft 2003). Importantly, the resistance phenotype
was maintained in the absence of drug for the 3 months it was monitored (Seifert et al.,
2003) With this line it was found that a transporter named LdMT a P-type ATPase is
responsible for inward translocation of miltefosine and that mutations in this gene were
found in a parasite with a resistant phenotype (Perez-Victoria, Castanys, & Gamarro,
2003). Wild type LdMT was transfected into the miltefosine resistant parasite and
miltefosine sensitivity was restored, proving its involvement in miltefosine resistance in
this line (Perez-Victoria, Gamarro, Ouellette, & Castanys, 2003)
Fatty acid and sterol metabolism was then explored comparing resistant and
sensitive promastigotes (Rakotomanga, Saint-Pierre-Chazalet, & Loiseau, 2005). It was
found that miltefosine resistance affects three lipid biochemical pathways; fatty acid
elongation, the desaturase system responsible for fatty acid alkyl chain unsaturation, and
the C-24-alkylation of sterols (Rakotomanga et al., 2005) It was then found that LdMT
has a beta subunit Ros3 and that both are required to form a functional transporter (PerezVictoria, Sanchez-Canete, Castanys, & Gamarro, 2006). Continuing with the search for
other possible mechanisms of resistance, it was found that when LiABCG4 was
overexpressed, the drug was effluxed, resulting in resistance (Castanys-Munoz, AlderBaerens, Pomorski, Gamarro, & Castanys, 2007). LiABCG4 overexpression has not been
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seen in a drug selected resistant parasite. Further characterization of LdMT inactivated
leishmania promastigotes was conduced in vitro using macrophages and in vivo using
mice (Seifert, Perez-Victoria, Stettler, Sanchez-Canete, Castanys, Gamarro, & Croft,
2007). It was found that when the promastigotes transformed to amastigotes in
macrophages and mice their miltefosine resistant phenotype was maintained.
Proteomic analysis of leishmania resistant to 80 µM of miltefosine showed
differences in levels of eIFA a eukaryotic initiation factor (Singh, Chavan, & Dey, 2008).
Recently, several L. major miltefosine resistant promastigotes have been cloned and their
genomes sequenced (Coelho, Boisvert, Mukherjee, Leprohon, Corbeil, & Ouellette,
2012). This work has shown that when a leishmania culture is exposed to miltefosine
each individual parasite can go under genetic modification independently of its neighbors
due to clonal replication (Coelho et al., 2012). The sequencing of the clones revealed
different mutations in LdMT, pyridoxal kinase, and α-adaptin genes, which resulted in
different IC50 values (Coelho et al., 2012). The culmination of over a decade of work on
miltefosine resistance has shown us that miltefosine resistance is multifactorial and
several mechanisms can be employed to deal with ever increasing drug pressure.
Current Reports of Clinical Miltefosine Resistance
Due to the long half-life of miltefosine and the relative ease in selecting resistant
strains in in vitro, it has been feared that miltefosine resistance would emerge in the field.
Currently there are only two reports in the literature of emerging miltefosine resistance.
The first report was from a leishmania/HIV co-infected woman from Algeria living in
France (Cojean, Houze, Haouchine, Huteau, Lariven, Hubert, Michard, Bories, Pratlong,
& Bras, 2012). She received treatment with miltefosine from 2001-2007 after several
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relapses. Isolates were collected and tested for miltefosine sensitivity after each course of
treatment. The first isolate has an IC50 of 5 µM and the last measured IC50 is 50 µM
(cojean, 2012). This dramatic 10 fold increase in IC50, is associated with a previously
reported and one novel mutation in the LdMT gene LinJ.13.1590.
In India, the sensitivity of leishmania parasites following treatment of patients
infected with visceral leishmaniasis was studied (Bhandari, Kulshrestha, Deep, Stark,
Prajapati, Ramesh, Sundar, Schonian, Dujardin, & Salotra, 2012). They found that the
IC50’s were in the normal range for patients after successful treatment, but the IC50’s
increased in cases of visceral leishmaniasis relapse and post kala-azar dermal
leishmaniasis (Bhandari, 2012). They decided to partially sequence the LdMT and
ldRos3 genes to find previously reported mutations and did not find any (Bhandari,
2012). Perhaps if they had sequenced the entire genes whey would have found mutations.
One fact remains is that miltefosine resistance is emerging and will become a serious
problem in the future. Continued surveillance and monitoring of the spread of miltefosine
is necessary for proper planning of public health interventions.
Miltefosine Resistance in This Work
Miltefosine resistant isolates are only beginning to emerge in the field. Therefore,
the past decade of research on miltefosine resistance has been conducted exclusively on
lab-selected strains. Unfortunately, all miltefosine resistant lines that have been created
are promastigote lines (insect stage), which are more tractable in the lab but less
clinically relevant than amastigotes (amastigote stage). We sought out to transform a
promastigote cell line into a stable axenic amastigote cell line and select for miltefosine
drug resistance in this axenic amastigote cell line via stepwise drug pressure.
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Currently there is only one L. donovani axenic amastigote cell line (1S-CL2D)
reported in the literature (Debrabant, Joshi, Pimenta, & Dwyer 2004). Our
MHOM/SD/75/1246/130/ Khartoum (WR 378) which is grown with similar pH and
temperature of 5.5 and 37 °C as 1S-CL2D, but they differ in that 1S-CL2D requires 5 %
CO2 while our cell line does not. Both axenic amastigote cell lines were demonstrated to
produce a greater parasite burden in both in vitro and in vivo. The
MHOM/SD/75/1246/130/ Khartoum (WR 378) is the only L. donovani axenic
amastigote cell line to show IC50 value changes between amastigotes and promastiotes
treated with standard antileishmanial drugs. The stage specific differences are important
when evaluating novel compounds for a drug discover program. The axenic amastigotes
are more relevant for drug discovery programs because they are mammalian stage.
However, there is controversy as to whether lab generate axenic amastigote cell lines are
truly amastigotes beyond morphological characteristics. Therefore, we used qRT-PCR to
measure expression of stage-associated genes to show that our axenic amastigotes have
genotypic characteristics similar to amastigotes found in macrophages. We found that the
axenic amastigotes expressed the amastigote specific gene LinJ.22.0670 (A2) while it
was not found in the promastigote stage. Additionally, we found greater expression of
LinJ.33.0860 (beta-tubulin) and LinJ.30.2990 (Glyceraldehyde 3-phosphate
dehydrogenase) genes in the promastigote stage. With this phenotypic and genotypic
characterization of our axenic amastigote cell line we were confident that induction of
miltefosine resistance on this line would constitute the first study of miltefosine
resistance on the clinically relevant amastigote stage.
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A stable highly resistant line was selected after only a few months and cloned.
Remarkably, the resistant line (Milt-R) has a 50 fold greater IC50 than its sensitive parent
(Milt-S) in the axenic amastigote assay and 62 fold greater in the infected macrophage
assay. This line along with its sensitive parent became the basis for studying miltefosine
drug resistant mechanisms. Milt-R’s miltefosine resistance was found to be stable over
time and maintained in vivo, using the infected hamster model. No cross-resistance was
found with standard antileishmanial drugs except for miltefosine analogs. In the search
for the mechanism(s) of miltefosine resistance we explored oxidative stress, drug efflux,
and drug transporters.
Cytochrome C is thought to be a target for miltefosine in leishmania and has been
shown to be found in the cytoplasm of the parasite when exposed to miltefosine (LuqueOrtega & Rivas, 2007). Also, L. donovani promastigotes exposed to miltefosine have
been shown to have a drop in intracellular ATP levels and a decrease in oxygen
consumption rate (Luque-Ortega & Rivas, 2007). Cytochrome C and B’s involvement in
miltefosine drug resistance has not been explored until now. No statistically significant
differences were found between Milt-S and Milt-R in terms of doubling times when
exposed to heat and H2O2 stress. However, it was found that an ex vivo resistant parasite
isolated form hamster liver (Milt-HR) was more tolerant of heat stress. We also found no
significant differences between Milt-S and R when exposed to cytochrome C and B
inhibitors. Nor did we find any mutations in cytochrome C and B’s genes. Using greiss
reagent to measure nitrate production as an estimation of nitrous oxide we found that
infected macrophages have a 20 % greater production of nitrous oxide when exposed to
miltefosine than not. When comparing nitrate production in the presence of miltefosine
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between Milt-S and Milt-R no statistically significant difference was found between
them. Therefore, miltefosine does cause oxidative stress but oxidative stress and
involvement of cytochrome C and B are not an explanation for miltefosine drug
resistance.
An L. major line resistant to daunomycin and miltefosine was shown to have
higher expression of MDR1 (Perez). LinJ.34.1060 (MDR1) is a p-glycoprotein found in
multidrug resistant parasites that effluxes drugs. We found no statistically significant
differences in expression of MDR1 between Milt-S and R. MDR1 is just one of many
transporters that could efflux the drug out of leishmania. We further explored the
involvement of drug efflux as a mechanism of miltefosine resistance by tagging
miltefosine with a florescent probe and watched its localization over time in Milt-S and
R. After 5 hours of exposure to fluorescent miltefosine the cytoplasm of Milt-S is clearly
filled with the drug. Up to 8 hours of exposure no drug was found in Milt-R. If drug
efflux was responsible for miltefosine resistance we would have been able to detect
fluorescence in the cytoplasm of Milt-R followed by clearance of the drug. Therefore,
drug efflux pumps are not a mechanism of miltefosine resistance in our axenic amastigote
cell line.
We found Milt-R is more sensitive to daunomycin a topoisomerase II inhibitor and
drugs that target topoisomerase IB. This exciting finding led us to explore reasoning
behind differential sensitivity to this class of drugs and its involvement in miltefosine
resistance. In humans, topoisomerase I is one protein coded by one gene and in
leishmania topoisomerase I is a complex to two proteins coded by two genes found on
separate chromosomes making it an exciting drug target. The topoisomerases are
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responsible for unwinding supercoiled DNA so genes can be transcribed. Topoisomerase
II is ATP mediated and nicks both strands of DNA while topoisomerase I nicks a single
strand. Measuring the DNA relaxation of extracted topoisomerase I on supercoiled DNA
we found that after 20 minutes Milt-R relaxed 30 % more supercoiled DNA than Milt-S.
Looking back over samples collected during discontinuous miltefosine drug pressure by
week four with an IC50 of 10 µM a significant difference in DNA relaxation was found
which persisted over the drug selection process. We also looked at the gene sequences
and RNA expression of LinJ.28.2450 (DNA topoisomerase ii), LinJ.34.3220 (DNA
topoisomerase IB, large subunit), and LinJ.04.0070 (DNA topoisomerase IB, small
subunit) in both Milt-S and Milt-R. No differences were found in gene sequences but
Milt-R was found to have increased gene expression both without drug pressure and
exposure to 3 µM of miltefosine. Theoretically, increased expression of topoisomerase I
and II results in more targets for the inhibitors increasing their sensitivity to
topoisomerase inhibitors. The increase in DNA relaxation in Milt-R is possibly due to the
increased expression of another gene that could be found with a microarray. If this
increase in sensitivity to topoisomerase I drugs proves to occur in the field than
topoisomerase I drugs may be an important tool to combat emergence of miltefosine drug
resistance.
In leishmania miltefosine has been shown to be influxed by a miltefosine transporter
LinJ.13.1590 (LdMT) and its beta subunit LinJ.32.1040 (Ros3) that are responsible for
inward translocation of miltefosine (Perez-Victoria et al., 2003; Perez-Victoria et al.,
2006). Mutations in either of these genes are associated with a resistant phenotype
(Perez-Victoria et al., 2003; Perez-Victoria et al., 2006). We found no mutations in Ros3
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but did find three mutations in LdMT: D897N, K919N, and V951F. Using
pyrosequencing we found these mutations accumulated over time and are associated with
three IC50 value shifts.
Whole genome sequencing of L. major revealed several mutations in the
miltefosine transporter, pyridoxal kinase, α-adaptin, and several genes with no
orthologues in L. donovani (Coelho et al., 2012). In our Milt-S and R parasites we
sequenced LinJ.30.1310 (pyridoxal kinase) and LinJ.07.0060 (α-adaptin) and found (24)
and (19) mutations respectively. Pyridoxal kinase is integral to the vitamin B6 pathway
and catalyzes the ATP-dependent phosphorylation of pyridoxal, pyridoxine into
pyridoxal-5’ phosphate, the active form of vitamin B6. In addition to these mutations we
found a decrease in expression of pyridoxal kinase in Milt-R. The vitamin B6 pathway
may be a target for miltefosine mechanism of actions, which would explain why there is
more expression of pyridoxal kinase in the presence of 3 µM of miltefosine. These
mutations occur late in the selection cycle in highly miltefosine resistant parasites, which
could be, do to selective pressure on the vitamin B6 pathway in Milt-R.
The adaptins are proteins that mediate the formation of vesicles and α-adaptin is a
marker for endocytosis. In culture it has been demonstrated that large quantities of
miltefosine will bind to albumin and enter the cell via endocytosis. We found several
mutations in this gene and found one SNP occurred late in the selection process by
pyrosequencing. Theoretically, selective pressure against the miltefosine-albumin
complex results in mutations in the α-adaptin gene. Our Milt-R line is the most drug
resistant leishmania line and would probably have the most selective pressure against α-
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adaptin. In addition to understanding the mechanism(s) of miltefosine resistance in L.
donovani it is important to understand the fitness of miltefosine resistance.
Understanding the fitness of parasites is critical for researchers studying drug
resistance and public health control effort programs in the field in terms of the impact of
dosing, counterfeit drugs, and rapidity of the spread of resistance. Classically, drug
resistance gives the parasite an advantage over its wild type counterparts in the presence
of drug and incurs a fitness cost in the absence of that drug. Leishmania has been shown
to incur a fitness advantage in the absence of drug when it is resistant to antimony. This
finding has important implications in the field because it has been shown to spread
quicker than the drug sensitive population confounding the already complex control
efforts. The fitness of miltefosine has never been published and neither have any studies
on drug resistance using axenic amastigotes been conducted. Using one of these SNPs as
a marker (LdMT D897N) we set out to determine the fitness of miltefosine resistant
parasites. The miltefosine resistant parasite displays a classic fitness cost in the absence
or sub IC50 drug pressure, which is the opposite of what has been reported for antimony
resistant leishmania. With drug pressure equal to the IC50 of miltefosine or higher the
Milt-R parasite has a fitness advantage.
Miltefosine resistance is a complex multifactorial process that warrants further
study. It will be interesting to repeat some of this work with clinical isolates that are
currently emerging to see if its relevant to miltefosine resistance in the field. Based on my
work and all other papers published the main constant is the occurrence of mutations in
the miltefosine transporter gene, LinJ.13.1590. It is important to note that different
mutations have been found throughout the gene and specific markers may not be relevant
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to detect resistant isolates quickly in a hospital setting. The whole gene should be
sequenced to detect mutations. It is likely that mutations nearly anywhere in this gene
will result in a resistant phenotype. This theory could be tested with site directed
mutagenesis throughout the gene.
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Figure A-1: LinJ.13.1590 (LdMT) Sequence Alignment
Alignment of LinJ.13.1590 (LdMT) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.13.1590 is a
3294 base pair sequence coding for a phospholipid-transporting ATPase-like protein.
Red highlights indicates mutations.
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Figure A-2: LinJ.02.0020 (cytochrome B) Sequence Alignment
Alignment of LinJ.02.0020 (cytochrome B) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.02.0020 is a
657 base pair sequence coding for a cytochrome b-domain protein, putative. Red
highlights indicate mutations detected.
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Figure A-3: LinJ.16.1380 (cytochrome C) Sequence Alignment
Alignment of LinJ.16.1380 (cytochrome C) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.16.1380 is a
663 base pair sequence coding for a cytochrome C protein, putative. Red highlights
indicate mutations detected.
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Figure A-4: LinJ.34.2460 (phospholipid-transporting ATPase-like protein)
Alignment of LinJ.34.2460 (phospholipid-transporting ATPase-like protein)
Nucleotide Sequences in L. infantum from TriTrypDB (top line), Milt-S (middle
line), and Milt-R (bottom). LinJ.34.2460 is a 4476 base pair sequence coding for a
phospholipid-transporting ATPase-like protein. Red highlights indicate mutations
detected.
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Figure A-5: LinJ.07.0060 (α-adaptin) Sequence Alignment
Alignment of LinJ.07.0060 (α-adaptin) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). α-adaptin is a 2886
base pair sequence coding for a α-adaptin-like protein. Red highlights indicate
mutations detected.
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Figure A-6: LinJ.32.1040 (Ros3) Sequence Alignment
Alignment of LinJ.32.1040 (Ros3) Nucleotide Sequences in L. infantum from
TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.32.1040 is a 909
base pair sequence coding for the beta-subunnit of LdMT. Red highlights indicate
mutations detected.
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Figure A-7: Linj.30.1310 (Pyridoxal Kinase) Sequence Alignment
Alignment of LinJ.30.1310 (pyridoxal kinase) Nucleotide Sequences in L. infantum
from TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom). LinJ.30.1310 is
a 909 base pair sequence coding for a pyridoxal kinase protein. Red highlights indicate
mutations detected.
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Figure A-8: LinJ.28.2450 (DNA topoisomerase ii) Sequence Alignment
Alignment of LinJ.28.2450 (DNA topoisomerase ii) Nucleotide Sequences in L.
infantum from TriTrypDB (top line), Milt-S (middle line), and Milt-R (bottom).
LinJ.28.2450 is a 3756 base pair sequence coding for a DNA topoisomerase ii protein.
Red highlights indicate mutations detected.
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Figure A-9: LinJ.34.3220 (DNA topoisomerase IB, large subunit) Sequence
Alignment
Alignment of LinJ.34.3220 (DNA topoisomerase IB, large subunit) Nucleotide
Sequences in L. infantum from TriTrypDB (top line), Milt-S (middle line), and Milt-R
(bottom). LinJ.34.3220 is a 1908 base pair sequence coding for a DNA topoisomerase
IB, large subunit protein. Red highlights indicate mutations detected.
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Figure A-10: LinJ.04.0070 (DNA topoisomerase IB, small subunit) Sequence
Alignment
Alignment of LinJ.04.0070 (DNA topoisomerase IB, small subunit) Nucleotide
Sequences in L. infantum from TriTrypDB (top line), Milt-S (middle line), and Milt-R
(bottom). LinJ.04.0070 is a 789 base pair sequence coding for a DNA topoisomerase
IB, small subunit protein. Red highlights indicate mutations detected.
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